[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 277
1. Schwer AL, Damek DM, Kavanagh BD, Gaspar LE, Lillehei K, Stuhr K, Chen C: A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys; 2008 Mar 15;70(4):993-1001
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eligible patients had pathologically proved recurrent anaplastic astrocytoma or glioblastoma.
  • Dose-limiting toxicity (DLT) was any Grade 3 toxicity.
  • Grade 1-2 gefitinib-related dermatitis and diarrhea were common (10 and 7 patients, respectively).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / therapy. Glioma / therapy. Neoplasm Recurrence, Local / therapy. Quinazolines / therapeutic use. Radiosurgery / methods
  • [MeSH-minor] Adult. Aged. Astrocytoma / drug therapy. Astrocytoma / surgery. Astrocytoma / therapy. Dose Fractionation. Female. Humans. Male. Maximum Tolerated Dose. Mental Status Schedule. Middle Aged. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17967517.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


2. Balkanov AS, Makarenko MF, Poliakov PIu, Kachkov IA: [Results of hyperfractionated radiation therapy used in combination with lomustin in malignant gliomas of the brain]. Zh Vopr Neirokhir Im N N Burdenko; 2005 Jul-Sep;(3):14-16; discussion 16-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The postoperative use of lomustin, a nitrosourea agent, was investigated for its impact on the efficiency of hyperfractionated radiation therapy performed in patients with glioblastoma and anaplastic astrocytoma of the brain.
  • A total of 35 patients (26 and 9 patients with glioblastoma and anaplastic astrocytoma, respectively) were followed up.
  • Lomustin in combination with hyperfractionated radiation therapy was found to have no effect on the survival of patients with glioblastoma and anaplastic astrocytoma.
  • [MeSH-minor] Adult. Age Factors. Aged. Case-Control Studies. Combined Modality Therapy. Cranial Irradiation. Dexamethasone / therapeutic use. Dose Fractionation. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485820.001).
  • [ISSN] 0042-8817
  • [Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko
  • [ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7BRF0Z81KG / Lomustine; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


3. Sathornsumetee S, Cao Y, Marcello JE, Herndon JE 2nd, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ, Rich JN: Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol; 2008 Jan 10;26(2):271-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.
  • The aim of these retrospective studies was to evaluate tumor vascularity and expression of components of the VEGF pathway and hypoxic responses as predictive markers for radiographic response and survival benefit from the bevacizumab and irinotecan therapy.
  • Tumor specimens collected at the time of diagnosis were available for further pathologic studies in 45 patients (75%).
  • RESULTS: Of 45 patients, 27 patients had glioblastoma multiforme, and 18 patients had anaplastic astrocytoma.
  • CONCLUSION: In this patient cohort, tumor expression levels of VEGF, the molecular target of bevacizumab, were associated with radiographic response, and the upstream promoter of angiogenesis, hypoxia, determined survival outcome, as measured from treatment initiation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Biomarkers, Tumor / analysis. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Female. Humans. Hypoxia. Male. Middle Aged. Neovascularization, Pathologic. Proportional Hazards Models. Radiography. Retrospective Studies. Survival Analysis. Treatment Outcome. Vascular Endothelial Growth Factor A / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3714-21 [15897568.001]
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):217-27 [16365183.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):473-7 [16428489.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):67-78 [16443950.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):727-35 [16418497.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):189-93 [16533878.001]
  • [Cites] Neurology. 2006 Apr 25;66(8):1258-60 [16636248.001]
  • [Cites] Nature. 2006 May 25;441(7092):437-43 [16724055.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):626-35 [16837971.001]
  • [Cites] Nat Clin Pract Neurol. 2006 May;2(5):232-3 [16932555.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5260-4 [17000656.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Hum Pathol. 2007 Apr;38(4):629-38 [17367605.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):880-7 [15956649.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] Cancer Metastasis Rev. 2007 Jun;26(2):299-310 [17415526.001]
  • [Cites] Nat Rev Neurosci. 2007 Aug;8(8):610-22 [17643088.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2601-6 [17577040.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3835-44 [17440098.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Histochem Cytochem. 2000 Aug;48(8):1103-10 [10898803.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2742-6 [12782577.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6130-4 [14559790.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(24):9361-74 [14645546.001]
  • [Cites] Cell Cycle. 2004 Feb;3(2):164-7 [14712082.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):21-7 [14769136.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1516-25 [10334539.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • (PMID = 18182667.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS054276; United States / NCI NIH HHS / CA / R01 CA116659; United States / NCI NIH HHS / CA / CA116659; United States / NINDS NIH HHS / NS / K02 NS047409; United States / NINDS NIH HHS / NS / NS047409; United States / NINDS NIH HHS / NS / R01 NS054276
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; 0H43101T0J / irinotecan; 2S9ZZM9Q9V / Bevacizumab; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ NIHMS508913; NLM/ PMC3930173
  •  go-up   go-down


Advertisement
4. Bussière M, Hopman W, Day A, Pombo AP, Neves T, Espinosa F: Indicators of functional status for primary malignant brain tumour patients. Can J Neurol Sci; 2005 Feb;32(1):50-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One hundred and seven patients had a histopathological diagnosis of glioblastoma multiforme, 23 of anaplastic astrocytoma and 13 of anaplastic oligodendroglioma.
  • The anaplastic oligodendroglioma group had lower mortality and maintained better KPS scores over time, as did patients receiving full treatment.
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neurosurgical Procedures. Prognosis. Radiotherapy. Survival Analysis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15825546.001).
  • [ISSN] 0317-1671
  • [Journal-full-title] The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • [ISO-abbreviation] Can J Neurol Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


5. Santosh V, Arivazhagan A, Sreekanthreddy P, Srinivasan H, Thota B, Srividya MR, Vrinda M, Sridevi S, Shailaja BC, Samuel C, Prasanna KV, Thennarasu K, Balasubramaniam A, Chandramouli BA, Hegde AS, Somasundaram K, Kondaiah P, Rao MR: Grade-specific expression of insulin-like growth factor-binding proteins-2, -3, and -5 in astrocytomas: IGFBP-3 emerges as a strong predictor of survival in patients with newly diagnosed glioblastoma. Cancer Epidemiol Biomarkers Prev; 2010 Jun;19(6):1399-408
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Grade-specific expression of insulin-like growth factor-binding proteins-2, -3, and -5 in astrocytomas: IGFBP-3 emerges as a strong predictor of survival in patients with newly diagnosed glioblastoma.
  • In view of this, we evaluated the expression of IGFBP isoforms (IGFBP-2, -3, and -5) during malignant progression of astrocytoma and their prognostic significance in glioblastoma.
  • Statistical methods were used to assess their grade-specific expression pattern and mRNA-protein intercorrelation.
  • Survival analyses were done on a uniformly treated, prospective cohort of adult patients with newly diagnosed glioblastoma (n = 136) by using Cox regression models.
  • RESULTS: The mean transcript levels of IGFBP-2 and -3 were significantly higher in glioblastomas (GBM) relative to anaplastic astrocytoma (AA), diffuse astrocytoma (DA), and controls whereas IGFBP-5 mRNA was higher in GBM relative to AA and controls (P < 0.05).
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Glioblastoma / metabolism. Insulin-Like Growth Factor Binding Protein 2 / biosynthesis. Insulin-Like Growth Factor Binding Protein 5 / biosynthesis. Insulin-Like Growth Factor Binding Proteins / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Cohort Studies. Disease Progression. Humans. Immunohistochemistry. Insulin-Like Growth Factor Binding Protein 3. Middle Aged. Polymerase Chain Reaction / methods. Prognosis. Prospective Studies. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AACR.
  • (PMID = 20501753.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IGFBP3 protein, human; 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / Insulin-Like Growth Factor Binding Protein 3; 0 / Insulin-Like Growth Factor Binding Protein 5; 0 / Insulin-Like Growth Factor Binding Proteins; 0 / RNA, Messenger
  •  go-up   go-down


6. Perry SL, Bohlin C, Reardon DA, Desjardins A, Friedman AH, Friedman HS, Vredenburgh JJ: Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. J Neurooncol; 2009 Oct;95(1):129-134
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients.
  • The purpose of this study was to determine the safety of tinzaparin for deep vein thrombosis prophylaxis in newly diagnosed grade III-IV malignant glioma patients.
  • Forty patients were enrolled into the study, 35 with glioblastoma multiforme and 5 with anaplastic astrocytoma.
  • Possible attributable toxicity was limited to two patients who developed CNS hemorrhages (one grade 1 and one grade 2) and one patient with an increase in liver enzymes (grade 3).
  • There were no patients with a grade 4 or 5 CNS hemorrhages or systemic hemorrhages >or=grade 2.
  • Tinzaparin at a fixed prophylactic dose is safe and may decrease the incidence of thromboembolic complications in brain tumor patients.
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Male. Middle Aged. Pulmonary Embolism / etiology. Pulmonary Embolism / prevention & control. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2130-5 [15699479.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] J Thromb Haemost. 2007 May;5(5):955-62 [17461929.001]
  • [Cites] Surg Neurol. 2008 Aug;70(2):117-21; discussion 121 [18262633.001]
  • [Cites] Neuro Oncol. 2008 Jun;10(3):355-60 [18436627.001]
  • [Cites] J Thromb Haemost. 2010 Sep;8(9):1959-65 [20598077.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3389-95 [10550132.001]
  • [Cites] Oncologist. 1999;4(6):443-9 [10631688.001]
  • [Cites] Arch Intern Med. 2000 Aug 14-28;160(15):2327-32 [10927730.001]
  • [Cites] Chest. 2001 Jan;119(1 Suppl):132S-175S [11157647.001]
  • [Cites] Semin Radiat Oncol. 2001 Apr;11(2):163-9 [11285554.001]
  • [Cites] Arch Intern Med. 2001 May 28;161(10):1268-79 [11371254.001]
  • [Cites] J Neurosurg Sci. 2001 Dec;45(4):195-201; discussion 201 [11912469.001]
  • [Cites] J Neurooncol. 2002 Aug;59(1):39-47 [12222837.001]
  • [Cites] J Neurol. 2002 Oct;249(10):1409-12 [12382158.001]
  • [Cites] Chest. 2002 Dec;122(6):1933-7 [12475829.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] N Engl J Med. 2003 Jul 10;349(2):109-11 [12853582.001]
  • [Cites] N Engl J Med. 2003 Jul 10;349(2):146-53 [12853587.001]
  • [Cites] South Med J. 2004 Feb;97(2):213-4 [14982286.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1944-8 [15143088.001]
  • [Cites] J Thromb Haemost. 2004 Aug;2(8):1266-71 [15304029.001]
  • [Cites] Ann Neurol. 1983 Mar;13(3):334-6 [6303201.001]
  • [Cites] JAMA. 1988 Sep 2;260(9):1255-8 [3404638.001]
  • [Cites] Lancet. 1992 Jul 18;340(8812):152-6 [1352573.001]
  • [Cites] Mayo Clin Proc. 1994 Apr;69(4):329-32 [8170176.001]
  • [Cites] Neurology. 1993 Jun;43(6):1111-4 [8170553.001]
  • [Cites] Thromb Haemost. 1996 Feb;75(2):233-8 [8815566.001]
  • [Cites] N Engl J Med. 1996 Sep 5;335(10):701-7 [8703169.001]
  • [Cites] N Engl J Med. 1997 Sep 4;337(10):688-98 [9278467.001]
  • [Cites] Br J Surg. 1997 Aug;84(8):1099-103 [9278651.001]
  • [Cites] Eur J Cancer. 1997 Sep;33(10):1592-6 [9389920.001]
  • [Cites] N Engl J Med. 1998 Jul 9;339(2):80-5 [9654538.001]
  • [Cites] J Formos Med Assoc. 1999 May;98(5):365-7 [10420706.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2123-9 [15699480.001]
  • (PMID = 19415455.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / K23 HL084233-02; United States / NHLBI NIH HHS / HL / K23 HL084233-03; United States / NHLBI NIH HHS / HL / K23 HL084233; United States / NHLBI NIH HHS / HL / K23 HL084233-01A1; United States / NHLBI NIH HHS / HL / K23-HL084233-02
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fibrinolytic Agents; 0 / Heparin, Low-Molecular-Weight; 7UQ7X4Y489 / tinzaparin
  • [Other-IDs] NLM/ NIHMS180651; NLM/ PMC2837514
  •  go-up   go-down


7. Zemanová Z, Kramar F, Babická L, Ransdorfová S, Melichercíková J, Hrabal P, Kozler P, Michalová K: Molecular cytogenetic stratification of recurrent oligodendrogliomas: utility of interphase fluorescence in situ hybridization (I-FISH). Folia Biol (Praha); 2006;52(3):71-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined 16 patients with histologically proved oligodendrogliomas (5x oligodendroglioma, 9x anaplastic oligodendroglioma, 2x anaplastic oligoastrocytoma).
  • However, in six of them additional genetic alterations typical for high-grade astrocytoma were found, which could have negative influence on the prognosis.
  • [MeSH-minor] Adult. Aged. Cell Nucleus / metabolism. Chromosome Aberrations. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 7 / genetics. Chromosomes, Human, Pair 9 / genetics. DNA Probes / metabolism. Female. Genome, Human / genetics. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17089917.001).
  • [ISSN] 0015-5500
  • [Journal-full-title] Folia biologica
  • [ISO-abbreviation] Folia Biol. (Praha)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / DNA Probes
  •  go-up   go-down


8. Liau CT, Wei KC, Tseng CK, Jung SM: Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma. Chang Gung Med J; 2005 Jan;28(1):16-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma.
  • BACKGROUND: We have reported that carmustine (BCNU) and cisplatin administered before, during, and after radiotherapy did not improve the survival of patients with high-grade astrocytomas and were associated with more serious toxicities than radiotherapy plus BCNU.
  • Of these, 20 had glioblastoma multiforme and 22 had anaplastic astrocytoma.
  • The median time to tumor progression was 7.2 months (range, 0-88.7 months) and median survival time was 13.3 months (range, 1.7-88.7 months).
  • This combined modality treatment program was associated with reversible grade 3 to 4 hematological toxicity in 10 patients, with grade 3 ototoxicity in one patient and grade 2 neurotoxicity in one patient.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Carmustine / administration & dosage. Cisplatin / administration & dosage. Female. Humans. Lomustine / administration & dosage. Male. Middle Aged. Procarbazine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15804144.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; Q20Q21Q62J / Cisplatin; U68WG3173Y / Carmustine
  •  go-up   go-down


9. Oshiro S, Tsugu H, Komatsu F, Ohnishi H, Ueno Y, Sakamoto S, Fukushima T, Soma G: Evaluation of intratumoral administration of tumor necrosis factor-alpha in patients with malignant glioma. Anticancer Res; 2006 Nov-Dec;26(6A):4027-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of intratumoral administration of tumor necrosis factor-alpha in patients with malignant glioma.
  • BACKGROUND: This study assessed safety and efficacy for intratumoral administration of tumor necrosis factor-a (TNF-SAM2) into the post-operative tumor cavity through an Ommaya reservoir for patients with malignant glioma.
  • MATERIALS AND METHODS: Seven patients with malignant glioma, comprising 3 cases with glioblastoma multiforme (GBM), 3 cases with anaplastic astrocytoma (AA) and 1 case with malignant ependymoma (ME) were included in the study.
  • TNF-SAM2 was administrated into the post-operative tumor cavity through a reservoir at a concentration of 1x10(4) U/body when recurrence was detected, or as initial induction therapy concomitant with radiotherapy.
  • RESULTS: Partial response to this regional immunotherapy was seen in 4 out of 7 patients, and 1 patient with GBM has remained clinically stable for >184 weeks without tumor progression.
  • With AA, 2 cases appeared to display slowed advance and longer times to tumor recurrence or regrowth.
  • [MeSH-major] Glioma / therapy. Tumor Necrosis Factor-alpha / administration & dosage
  • [MeSH-minor] Adult. Aged. Female. Humans. Injections, Intralesional. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17195453.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / TNF-SAM2; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


10. Yamada K, Takeshima H, Sakurama T, Kuratsu J: Secondary cervical dystonia following stereotactic radiosurgery in a patient with thalamic glioma. Surg Neurol; 2007 Dec;68(6):665-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE DESCRIPTION: A 27-year-old woman complaining of headache and left motor weakness was found to have a thalamic tumor on the right side.
  • Histopathologically, tumor samples manifested features of anaplastic astrocytoma.
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Necrosis. Thalamus / pathology. Thalamus / surgery


11. Mahasittiwat P, Mizoe JE, Hasegawa A, Ishikawa H, Yoshikawa K, Mizuno H, Yanagi T, Takagi R, Pattaranutaporn P, Tsujii H: l-[METHYL-(11)C] methionine positron emission tomography for target delineation in malignant gliomas: impact on results of carbon ion radiotherapy. Int J Radiat Oncol Biol Phys; 2008 Feb 1;70(2):515-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND MATERIALS: This retrospective study analyzed 16 patients with malignant glioma (4 patients, anaplastic astrocytoma; 12 patients, glioblastoma multiforme) treated with surgery and carbon ion radiotherapy from April 2002 to Nov 2005.
  • The MET-PET target volume was compared with gross tumor volume and CTV, defined by using computed tomography/magnetic resonance imaging (MRI).
  • [MeSH-major] Astrocytoma / radionuclide imaging. Brain Neoplasms / radionuclide imaging. Carbon Radioisotopes. Glioblastoma / radionuclide imaging. Methionine. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Radiotherapy Planning, Computer-Assisted / methods. Retrospective Studies. Tomography, X-Ray Computed / methods. Tumor Burden

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17900820.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Case Reports; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; AE28F7PNPL / Methionine
  •  go-up   go-down


12. Moulding HD, Friedman DP, Curtis M, Kenyon L, Flanders AE, Paek SH, Andrews DW: Revisiting anaplastic astrocytomas I: an expansive growth pattern is associated with a better prognosis. J Magn Reson Imaging; 2008 Dec;28(6):1311-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Revisiting anaplastic astrocytomas I: an expansive growth pattern is associated with a better prognosis.
  • PURPOSE: To study whether anaplastic astrocytomas that are nonenhancing and/or well-circumscribed (expansive) are associated with a better prognosis.
  • MATERIALS AND METHODS: We retrospectively identified 59 patients with pathologically confirmed World Health Organizaiton (WHO) grade III anaplastic astrocytoma who underwent craniotomy at our institution from 1995 through 2006.
  • A multivariate (Cox proportional hazards) analysis showed that patient age and expansive tumor phenotype affected outcome, whereas RPA class, enhancement, and GTR did not.
  • CONCLUSION: Circumscribed growth in histologically proven anaplastic astrocytoma, which has not been emphasized in past studies, has a considerable survival advantage.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Chi-Square Distribution. Contrast Media. Craniotomy. Female. Gadolinium DTPA. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Retrospective Studies. Statistics, Nonparametric. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 19025897.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


13. Camacho LH, Olson J, Tong WP, Young CW, Spriggs DR, Malkin MG: Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest New Drugs; 2007 Apr;25(2):131-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Phenylbutyrate (PBA), and its metabolite phenylacetate (PAA), induce growth inhibition and cellular differentiation in multiple tumor models.
  • Twenty-one patients with the following malignancies were treated: colon carcinoma 4, non-small cell lung carcinoma 4; anaplastic astrocytoma 3, glioblastoma multiforme 3, bladder carcinoma 2, sarcoma 2, and ovarian carcinoma, rectal hemangiopericytoma, and pancreatic carcinoma 1 each.
  • Common adverse effects included grade 1 nausea/vomiting, fatigue, and lightheadedness.
  • Two patients with anaplastic astrocytoma and a patient with glioblastoma remained stable without tumor progression for 5, 7, and 4 months respectively.
  • [MeSH-minor] Adult. Aged. Biotransformation. Disease Progression. Dose-Response Relationship, Drug. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1992 Nov 15;80(10):2604-9 [1421378.001]
  • [Cites] Clin Cancer Res. 1996 Feb;2(2):379-87 [9816181.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):672-81 [7674018.001]
  • [Cites] Angiology. 1956 Apr;7(2):156-8 [13314153.001]
  • [Cites] Blood. 1993 Oct 1;82(7):2203-9 [7691251.001]
  • [Cites] Adv Exp Med Biol. 1997;400A:501-5 [9547596.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3047-55 [11595694.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2A):1099-103 [9615772.001]
  • [Cites] Cancer Res. 1988 Dec 15;48(24 Pt 1):7304-9 [3191501.001]
  • [Cites] J Clin Pharmacol. 1995 Apr;35(4):368-73 [7650225.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):177-82 [15831235.001]
  • [Cites] Med Pediatr Oncol. 2000 Dec;35(6):577-81 [11107121.001]
  • [Cites] Int J Oncol. 1998 Apr;12(4):889-93 [9499451.001]
  • [Cites] Br J Haematol. 1991 Oct;79 Suppl 1:81-3 [1931716.001]
  • [Cites] Ther Drug Monit. 1996 Dec;18(6):714-20 [8946671.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1690-4 [8137283.001]
  • [Cites] Cancer Chemother Pharmacol. 2001 May;47(5):385-90 [11391852.001]
  • [Cites] Leukemia. 2006 Feb;20(2):212-7 [16357841.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3906-11 [15851763.001]
  • [Cites] Stat Med. 1991 Nov;10(11):1647-64 [1792460.001]
  • [Cites] Cancer Res. 1992 Apr 1;52(7):1988-92 [1372534.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):963-70 [11948101.001]
  • [Cites] N Engl J Med. 1984 Jun 21;310(25):1630-4 [6427608.001]
  • [Cites] Clin Cancer Res. 1996 May;2(5):865-72 [9816242.001]
  • [Cites] Blood. 1989 Apr;73(5):1298-306 [2467706.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):3998-4002 [11358817.001]
  • [Cites] Pediatr Res. 1991 Feb;29(2):147-50 [2014149.001]
  • [Cites] Int J Cancer. 1995 Feb 8;60(4):507-14 [7829265.001]
  • [Cites] Clin Cancer Res. 1999 Jun;5(6):1509-16 [10389940.001]
  • [Cites] Jpn J Ophthalmol. 2000 Nov-Dec;44(6):601-9 [11094173.001]
  • [Cites] J Cell Biochem. 2004 Nov 1;93(4):819-29 [15389886.001]
  • [Cites] Am J Physiol. 1998 May;274(5 Pt 1):E801-7 [9612237.001]
  • [Cites] Blood. 1992 Sep 15;80(6):1576-81 [1381630.001]
  • [Cites] Cell Growth Differ. 1996 Dec;7(12):1609-15 [8959328.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2292-300 [11489804.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2932-8 [7773944.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2923-7 [8187079.001]
  • [Cites] Anticancer Res. 2004 Sep-Oct;24(5A):2765-71 [15517883.001]
  • [Cites] Leukemia. 1999 Aug;13(8):1243-53 [10450753.001]
  • [Cites] J Natl Cancer Inst. 1998 Nov 4;90(21):1621-5 [9811311.001]
  • (PMID = 17053987.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01: CA69856
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Phenylbutyrates
  •  go-up   go-down


14. Ray WZ, Blackburn SL, Casavilca-Zambrano S, Barrionuevo C, Orrego JE, Heinicke H, Dowling JL, Perry A: Clinicopathologic features of recurrent dysembryoplastic neuroepithelial tumor and rare malignant transformation: a report of 5 cases and review of the literature. J Neurooncol; 2009 Sep;94(2):283-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features of recurrent dysembryoplastic neuroepithelial tumor and rare malignant transformation: a report of 5 cases and review of the literature.
  • Nonetheless, a probably radiation induced anaplastic astrocytoma was encountered in one case 7 years after therapy.
  • These findings suggest that these patients may need closer follow-up than initially suggested, lending further support to the notion that this tumor behaves more like a benign neoplasm, rather than a dysplastic or hamartomatous lesion.
  • [MeSH-major] Brain Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplasms, Neuroepithelial / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Magnetic Resonance Imaging. Male. Young Adult


15. Compostella A, Tosoni A, Blatt V, Franceschi E, Brandes AA: Prognostic factors for anaplastic astrocytomas. J Neurooncol; 2007 Feb;81(3):295-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for anaplastic astrocytomas.
  • Anaplastic astrocytomas (WHO grade III) constitute about 10% of all gliomas.
  • Definitive data on predictive and prognostic factors are lacking for these neoplasms that are considered the most enigmatic entity among the whole spectrum of astrocytic tumors because of their unclear biologic behavior and variable clinical outcome.
  • Currently, only few factors have been identified as useful for prognosis of anaplastic astrocytoma: age and Karnofsky Performance Status.
  • Potential prognostic biomarkers concern tumor suppressor genes on chromosome 9q that are involved in the RB1 pathway; PTEN, the PI3k/Akt/p70s6k cascade, survivin gene, Formylpeptide receptor, minichromosome maintenance protein 3 and genes on chromosome 7.
  • The state of the art pictured here underlie the recent interest on gene expression profile to identify aberrations useful to understand the biologic behavior of astrocytic tumors.
  • [MeSH-major] Astrocytoma / genetics. Astrocytoma / pathology. Biomarkers, Tumor / analysis. Brain Neoplasms / genetics. Brain Neoplasms / pathology
  • [MeSH-minor] Adult. Age Factors. Aged. Gene Expression Profiling. Humans. Karnofsky Performance Status. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1988 Nov 15;62(10):2152-65 [3179928.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1461-8 [12684420.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1926-33 [15143086.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):213-6 [16365177.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] J Neurooncol. 2005 Jan;71(2):85-9 [15690121.001]
  • [Cites] Cancer. 1996 Mar 15;77(6):1161-6 [8635139.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16759-64 [16267128.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5167-74 [16033832.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6503-10 [15374961.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Cancer. 1999 Aug 15;86(4):672-83 [10440696.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10 (15):4933-8 [15297393.001]
  • [Cites] Neurosurgery. 1991 Apr;28(4):496-501 [1851971.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4694-700 [9788624.001]
  • [Cites] Nat Genet. 1997 Apr;15(4):356-62 [9090379.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Apr;21(4):340-6 [9559346.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1063-71 [12569607.001]
  • [Cites] Proteomics. 2005 Mar;5(4):1167-77 [15759318.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1063-8 [11844831.001]
  • [Cites] Neurosurgery. 1992 Oct;31(4):636-42; discussion 642 [1407448.001]
  • [Cites] J Neurooncol. 2001 Dec;55(3):195-204 [11859975.001]
  • [Cites] CA Cancer J Clin. 1990 Jan-Feb;40(1):9-26 [2104569.001]
  • [Cites] J Neuropathol Exp Neurol. 1996 Jan;55(1):81-7 [8558174.001]
  • [Cites] Am J Hum Genet. 1996 Jun;58(6):1260-7 [8651304.001]
  • [Cites] Science. 1997 Mar 28;275(5308):1943-7 [9072974.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7683-8 [11606412.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56 [11504770.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10 (6):1871-4 [15041700.001]
  • [Cites] J Pathol. 1994 Dec;174(4):275-82 [7884589.001]
  • [Cites] Neuropathol Appl Neurobiol. 2000 Aug;26(4):319-31 [10931365.001]
  • [Cites] Neuroradiology. 1997 May;39(5):348-50 [9189880.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):436-51 [16212809.001]
  • [Cites] Neurosurgery. 2004 Feb;54(2):349-57; discussion 357 [14744281.001]
  • [Cites] Cancer. 1985 Sep 1;56(5):1106-11 [2990664.001]
  • [Cites] Oncogene. 1995 Jun 1;10(11):2243-6 [7784070.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Jun;13(2):86-93 [7542911.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):779-86 [11549567.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 1;97(11):823-35 [15928303.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):233-47 [16612574.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):249-58 [15671553.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7674-81 [16140934.001]
  • [Cites] Br J Cancer. 2005 Jul 11;93(1):124-30 [15970925.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4151-8 [14519639.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] J Neurooncol. 2002 Jul;58(3):203-15 [12187956.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Mar;21(3):195-206 [9523194.001]
  • [Cites] Oncogene. 1996 Sep 5;13(5):983-94 [8806688.001]
  • [Cites] Neuropathol Appl Neurobiol. 2004 Jun;30(3):267-78 [15175080.001]
  • [Cites] Cancer. 2005 Dec 15;104(12):2775-83 [16284993.001]
  • [Cites] J Neurooncol. 2004 Jul;68(3):275-83 [15332332.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Nov-Dec;26(10):2466-74 [16286386.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • (PMID = 17001519.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 55
  •  go-up   go-down


16. Ghauri AJ, Musadiq M, Sha Y, Elsherbiny S: Late onset of subfoveal choroidal neovascularisation following cerebral radiotherapy. BMJ Case Rep; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 43-year-old Caucasian man presented with a 4-week history of sudden loss of central vision in the left eye, 8.5 years following radical radiotherapy for left tempero-parietal anaplastic astrocytoma.
  • [MeSH-major] Astrocytoma / radiotherapy. Brain Neoplasms / radiotherapy. Choroidal Neovascularization / etiology
  • [MeSH-minor] Adult. Blindness / etiology. Fluorescein Angiography. Humans. Male. Retina / radiation effects

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Rev. 2004 Aug;25(4):581-611 [15294883.001]
  • [Cites] Retina. 1987 Fall;7(3):156-61 [2447622.001]
  • [Cites] Eye (Lond). 1990;4 ( Pt 1):195-203 [2323471.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):599-605 [10348290.001]
  • [Cites] Clin Experiment Ophthalmol. 2006 Aug;34(6):625-6 [16925720.001]
  • [Cites] BMC Ophthalmol. 2007;7:6 [17411428.001]
  • [Cites] Acta Ophthalmol Scand. 2007 May;85(3):240-50 [17488452.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):974-7 [18313522.001]
  • [Cites] J Neurosurg. 2003 Sep;99(3):467-73 [12959431.001]
  • [Cites] Am J Ophthalmol. 2002 May;133(5):709-11 [11992875.001]
  • (PMID = 22797201.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3027866
  •  go-up   go-down


17. Vogelbaum MA, Berkey B, Peereboom D, Macdonald D, Giannini C, Suh JH, Jenkins R, Herman J, Brown P, Blumenthal DT, Biggs C, Schultz C, Mehta M: Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro Oncol; 2009 Apr;11(2):167-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131.
  • The primary objectives of this phase II study were to evaluate the use of preirradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed anaplastic oligodendroglioma (AO) and mixed anaplastic oligoastrocytoma (MOA).
  • Tumor tissue was analyzed for the presence of chromosomal deletions on 1p and 19q and for MGMT-promoter methylation.
  • The worst nonhematological toxicity was grade 4 in three patients (8%).
  • There were no grade 4 nonhematological toxicities during the concurrent chemotherapy and RT.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Astrocytoma / therapy. Brain Neoplasms / therapy. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / therapy. Oligodendroglioma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Combined Modality Therapy. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Dose Fractionation. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Prognosis. Promoter Regions, Genetic. Survival Rate. Treatment Outcome. Tumor Suppressor Proteins / genetics. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Treat Rev. 1997 Jan;23(1):35-61 [9189180.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Oncogene. 1999 Jul 15;18(28):4144-52 [10435596.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] Neuro Oncol. 2007 Jul;9(3):314-8 [17435180.001]
  • [Cites] J Neurosurg. 1996 Oct;85(4):602-7 [8814163.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):825-30 [11020580.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2449-55 [11331324.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4689-92 [11406538.001]
  • [Cites] Neurology. 2001 Jul 24;57(2):340-2 [11468326.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):552-60 [11905710.001]
  • [Cites] J Neurooncol. 2003 Feb;61(3):267-73 [12675321.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] J Neurooncol. 2003 Sep;64(3):271-8 [14558604.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] J Neurosurg. 1985 Dec;63(6):881-9 [4056902.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4363-7 [9766665.001]
  • (PMID = 18779504.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  • [Other-IDs] NLM/ PMC2718988
  •  go-up   go-down


18. Tanaka S, Kobayashi I, Utsuki S, Iwamoto K, Takanashi J: Biopsy of brain stem glioma using motor-evoked potential mapping by direct peduncular stimulation and individual adjuvant therapy. Case report. Neurol Med Chir (Tokyo); 2005 Jan;45(1):49-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Partial resection of the tumor was safely performed, with slight temporary neurological worsening.
  • The histological diagnosis was anaplastic astrocytoma.
  • Individual adjuvant therapy based on the results of real-time reverse transcription-polymerase chain reaction of O6-methylguanine-deoxyribonucleic acid methyltransferase achieved an almost complete tumor response.
  • [MeSH-major] Astrocytoma / surgery. Brain Mapping. Brain Stem Neoplasms / surgery. Evoked Potentials, Motor. Mesencephalon / physiopathology. Neurosurgical Procedures / methods
  • [MeSH-minor] Adult. Biopsy / methods. Humans. Male

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15699622.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Mott RT, Turner KC, Bigner DD, McLendon RE: Utility of EGFR and PTEN numerical aberrations in the evaluation of diffusely infiltrating astrocytomas. Laboratory investigation. J Neurosurg; 2008 Feb;108(2):330-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Given the important roles for EGFR and PTEN in the malignant progression of astrocytomas, the authors hypothesized that the fraction of tumor cells with aberrations in these genetic loci would correlate with the histological grade.
  • METHODS: The authors evaluated 217 consecutive diffusely infiltrating astrocytomas that were graded using the WHO guidelines, including 16 diffuse astrocytomas (WHO Grade II), 72 anaplastic astrocytomas ([AAs] WHO Grade III), and 129 glioblastomas multiforme ([GBMs] WHO Grade IV).
  • RESULTS: The population of tumor cells with polysomy of chromosome 7 and the EGFR locus and monosomy of chromosome 10 and the PTEN locus correlated significantly with histological grade.
  • In particular, high-grade astrocytomas (that is, AAs and GBMs) had elevated fractions of tumor cells with polysomy of chromosome 7 and the EGFR locus and monosomy of chromosome 10 and the PTEN locus.
  • Using these findings, the authors generated a mathematical model capable of subcategorizing high-grade astrocytomas.
  • The successful model incorporated only the percentage of tumor cells with polysomy of EGFR and monosomy of PTEN, as well as patient age.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Chromosome Aberrations. Genes, erbB-1 / genetics. PTEN Phosphohydrolase / genetics
  • [MeSH-minor] Adult. Age Factors. Aneuploidy. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Chromosome Mapping. Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 7 / genetics. Disease Progression. Glioblastoma / genetics. Glioblastoma / pathology. Humans. In Situ Hybridization, Fluorescence. Middle Aged. Models, Biological. Monosomy / genetics. Survival Rate


20. Sadones J, Michotte A, Veld P, Chaskis C, Sciot R, Menten J, Joossens EJ, Strauven T, D'Hondt LA, Sartenaer D, Califice SF, Bierau K, Svensson C, De Grève J, Neyns B: MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. Eur J Cancer; 2009 Jan;45(1):146-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.
  • AIMS: To investigate the correlation between O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and benefit from temozolomide in patients with recurrent high-grade glioma.
  • RESULTS: A subgroup of 38 patients who were chemotherapy-naive at recurrence was analysed (22 glioblastoma, 12 anaplastic astrocytoma [AA] and 4 anaplastic oligoastrocytoma [AOA]); none had 1p/19q loss.
  • By Cox multivariate analysis, tumour grade and MGMT promoter methylation correlated with time to progression (p<0.05); MGMT promoter methylation correlated with superior overall survival in AA/AOA but not in glioblastoma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. O(6)-Methylguanine-DNA Methyltransferase / genetics. Promoter Regions, Genetic
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA Methylation. Female. Glioblastoma / drug therapy. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality. Prognosis. Retrospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18945611.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


21. Callovini GM: Is it appropriate to redefine the indication for stereotactic brain biopsy in the MRI Era? Correlation with final histological diagnosis in supratentorial gliomas. Minim Invasive Neurosurg; 2008 Apr;51(2):109-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The aim of this study was to evaluate the advisability of modifying the indications for stereotactic brain biopsy (SBB) in high- and low-grade supratentorial glial tumors in correlation with the diagnostic accuracy of magnetic resonance imaging (MRI).
  • On the basis of the MRI findings the patients were divided into two groups: high-grade (n=107) and low-grade (n=67) gliomas.
  • In the group of high-grade gliomas (HGG) there was diagnostic coincidence in 87% of cases, reaching 100% in lesions of the corpus callosum.
  • In the group of low-grade gliomas (LGG) there was diagnostic coincidence in 63% (42 cases), whereas there was discordance in 30%: 10 cases were upgraded to anaplastic astrocytoma, and in 10 cases no tumors were observed at all.
  • Today, the indications for biopsy in lesions mimicking high-grade gliomas are mainly linked to the site of the tumor, coexisting differential diagnoses or more than one treatment option.
  • On the contrary, in lesions where MRI findings indicate low-grade gliomas, grading is crucial also in order to avoid treatment inappropriate in non-neoplastic lesions.
  • [MeSH-major] Astrocytoma / pathology. Brain / pathology. Glioma / pathology. Magnetic Resonance Imaging / standards. Neoplasm Recurrence, Local / pathology. Stereotaxic Techniques / standards. Supratentorial Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Corpus Callosum / pathology. Corpus Callosum / radiography. Diagnosis, Differential. Diagnostic Errors / prevention & control. Female. Humans. Male. Middle Aged. Necrosis. Observer Variation. Predictive Value of Tests. Radiation Injuries / pathology. Radiation Injuries / radiography. Retrospective Studies. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18401825.001).
  • [ISSN] 0946-7211
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


22. Bäcklund LM, Nilsson BR, Liu L, Ichimura K, Collins VP: Mutations in Rb1 pathway-related genes are associated with poor prognosis in anaplastic astrocytomas. Br J Cancer; 2005 Jul 11;93(1):124-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations in Rb1 pathway-related genes are associated with poor prognosis in anaplastic astrocytomas.
  • Anaplastic astrocytoma (AA, WHO grade III) is, second to Glioblastoma, the most common and most malignant type of adult CNS tumour.
  • The survival data on 37 carefully sampled AA was correlated with the results of a detailed analysis of the status of nine genes known to be involved in the development of astrocytic tumours.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Genes, Retinoblastoma. Mutation
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Prognosis


23. Ducray F, Dutertre G, Ricard D, Gontier E, Idbaih A, Massard C: [Advances in adults' gliomas biology, imaging and treatment]. Bull Cancer; 2010 Jan;97(1):17-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In anaplastic gliomas ongoing studies depend on 1p/19q codeletion status and in glioblastomas on MGMT methylation status.
  • Advanced brain tumor imaging elicits a better identification of gliomas evolutive potential of.
  • In low-grade gliomas, the importance of maximal resection and the role of chemotherapy are being increasingly recognized.
  • In anaplastic gliomas, phase III studies have clarified the respective roles of chemotherapy and radiotherapy.
  • [MeSH-minor] Adult. Astrocytoma / diagnosis. Astrocytoma / genetics. Astrocytoma / therapy. Combined Modality Therapy / methods. Diagnostic Imaging / methods. Humans. Oligodendroglioma / diagnosis. Oligodendroglioma / genetics. Oligodendroglioma / therapy. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20028650.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  • [Number-of-references] 166
  •  go-up   go-down


24. Maiti AK, Ghosh K, Chatterjee U, Chakrobarti S, Chatterjee S, Basu S: Epidermal growth factor receptor and proliferating cell nuclear antigen in astrocytomas. Neurol India; 2008 Oct-Dec;56(4):456-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: The involvement of various growth factors, growth factor receptors and proliferative markers in the molecular pathogenesis of astrocytic neoplasms are being studied extensively.
  • Since EGFR and proliferating cell nuclear antigen (PCNA) are involved in mitogenic signal transduction and cellular proliferation pathway, we have studied the correlation between the expression of EGFR and PCNA labeling index in astrocytic tumors.
  • MATERIALS AND METHODS: We investigated the immunohistochemical expression of EGFR and PCNA using the appropriate monoclonal antibodies in 40 cases of astrocytic tumors of which 21 cases were glioblastoma, eight cases were Grade III or anaplastic astrocytomas and six cases were Grade II or diffuse astrocytomas and five cases were Grade I or pilocytic astrocytomas.
  • RESULTS: Both the EGFR expression and PCNA labeling index increase with increasing grades of astrocytomas with a significantly high percentage of cells showing positive staining for both EGFR and PCNA in GBM and Grade III astrocytomas compared to Grade II astrocytomas.
  • The expression levels of both EGFR and PCNA were low in Grade I or pilocytic astrocytomas.
  • CONCLUSIONS: A significant correlation was found between EGFR overexpression and PCNA labeling index in Grade III and Grade II astrocytomas and glioblastoma.
  • These suggest that the tumor proliferation, at least in higher grades of astrocytomas is dependent in some measure on EGF and EGFR-related signaling pathways.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Proliferating Cell Nuclear Antigen / metabolism. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Male. Middle Aged


25. Parafiniuk D, Jezewski D, Nowacki P: [Malignant astrocytoma as a recurrance of astrocytoma II WHO after 13 years. Case report and literature review]. Ann Acad Med Stetin; 2010;56(2):45-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant astrocytoma as a recurrance of astrocytoma II WHO after 13 years. Case report and literature review].
  • Astrocytomas--neroepithelial originated tumors that belong to the big, differential group of tumors, which derive from astrocytic glial.
  • They include slow growing tumors such as fibillary astrocytoma or very malignant glioblastoma multiforme.
  • The case which is being presented is of a forty nine year old woman operated in July 1997 because of a protoplasmic astrocytoma II WHO in the left frontal lobe.
  • Due to this adverse event MRI was ordered and suspicion of tumor recurrence was put forward.
  • Histopathology identified anaplastic astrocytoma III WHO.
  • According to literature, the factors regarding remission time, tumor malignancy and therapeutic aim were analyzed.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Astrocytoma. Female. Frontal Lobe. Humans. Reoperation. Seizures / etiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21473001.001).
  • [ISSN] 1427-440X
  • [Journal-full-title] Annales Academiae Medicae Stetinensis
  • [ISO-abbreviation] Ann Acad Med Stetin
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Poland
  •  go-up   go-down


26. Buckner JC, O'Fallon JR, Dinapoli RP, Schomberg PJ, Farr G, Schaefer P, Giannini C, Scheithauer BW, Ballman KV: Prognosis in patients with anaplastic oligoastrocytoma is associated with histologic grade. J Neurooncol; 2007 Sep;84(3):279-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis in patients with anaplastic oligoastrocytoma is associated with histologic grade.
  • BACKGROUND: Anaplastic oligoastrocytomas (AOA) are relatively uncommon high-grade gliomas.
  • METHODS: Between 1980 and 1999, Mayo Clinic and the NCCTG conducted 10 trials of radiation therapy and chemotherapy in adults with newly-diagnosed high-grade gliomas.
  • We grouped patients by cell type and grade, compared survival distributions by the log-rank statistic, and performed multiple variable analyses.
  • RESULTS: Of 1368 patients, 68 (5%) had AOA, including 21 Grade 3 (OA3) and 47 grade 4 (OA4), 153 (11%) had anaplastic astrocytoma (AA), and 1147 (84%) had glioblastoma multiforme (GBM).
  • CONCLUSIONS: Patients with anaplastic oligoastrocytoma have distinct outcomes based upon grade (OA3 vs. OA4) and in comparison with pure astrocytoma (AA or GBM).
  • Future trials which include more than one histologic entity need to report results by cell type and grade and account for the varying prognoses in interpreting treatment outcomes.
  • [MeSH-major] Astrocytoma / mortality. Astrocytoma / pathology. Brain Neoplasms / mortality. Brain Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Clinical Trials as Topic. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Anaplastic Oligoastrocytoma.
  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] Stat Med. 1992 Dec;11(16):2093-109 [1293671.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Cancer Treat Rep. 1983 Feb;67(2):121-32 [6337710.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Oct;56(10):1098-104 [9329453.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1175-90 [7977648.001]
  • [Cites] Neurosurgery. 1993 Mar;32(3):365-70; discussion 371 [8455760.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Mar;60(3):248-62 [11245209.001]
  • [Cites] Biometrics. 1992 Jun;48(2):411-25 [1637970.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):911-4 [9276354.001]
  • [Cites] Int J Cancer. 1995 Jun 22;64(3):207-10 [7622310.001]
  • [Cites] Neurosurgery. 1994 Apr;34(4):577-82; discussion 582 [8008153.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] J Neurosurg. 1992 May;76(5):741-5 [1564535.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5419-26 [17135643.001]
  • [Cites] Int J Cancer. 1994 Apr 15;57(2):172-5 [8157354.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • (PMID = 17431544.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Kumar R, Kamdar D, Madden L, Hills C, Crooks D, O'Brien D, Greenman J: Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients. Oncol Rep; 2006 Jun;15(6):1513-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients.
  • Patients were divided into various groups depending on their histological diagnosis: meningioma (n=11), anaplastic astrocytoma (n=4) and glioblastoma multiforme (GBM; n=46).
  • Significant reduction in serum IL-12 was seen in all groups as compared with the controls: meningioma, p=0.03; anaplastic astrocytoma, p<0.001; and GBM, p<0.001.
  • Conversely, serum IL-10 was significantly increased in anaplastic astrocytoma, p=0.02, and GBM, p=0.03.
  • [MeSH-major] Astrocytoma / immunology. Brain Neoplasms / immunology. Glioblastoma / immunology. Interleukin-10 / blood. Interleukin-12 / blood. Meningioma / immunology. Th1 Cells / immunology. Th2 Cells / immunology
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Humans. Male. Middle Aged


28. Garcia-Navarrete R, Garcia E, Arrieta O, Sotelo J: Hepatocyte growth factor in cerebrospinal fluid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value. J Neurooncol; 2010 May;97(3):347-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant gliomas--glioblastoma multiforme and anaplastic astrocytoma--are among the most fatal forms of cancer in humans.
  • It has been suggested that hepatocyte growth factor (HGF) is a reliable predictor of glioma malignancy; amounts of HGF are directly related to cellular proliferation, angiogenesis, low apoptotic rate, and poor prognosis (WHO III and IV).
  • We measured the HGF content of cerebrospinal fluid (CSF) from patients with malignant glioma glioblastoma multiforme (WHO IV; n = 14), anaplastic astrocytoma (WHO III; n = 4), and meningioma (WHO I; n = 9), and from control subjects (n = 25), and found a high concentration of HGF in patients with malignant glioma.
  • However, CSF concentrations from glioblastoma multiforme and anaplastic astrocytoma patients were not statistically significantly different (893 +/- 157 vs. 728 +/- 61, respectively; P > 0.01).
  • CSF concentrations of HGF higher than 500 pg/ml were associated with increased mortality whereas values higher than 850 pg/ml were associated with a brief tumor-free period after surgery (9 +/- 0.6 vs. 6 +/- 0.6 months, respectively, P < 0.001).
  • [MeSH-minor] Adult. Analysis of Variance. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):129-38 [15015778.001]
  • [Cites] Cancer Lett. 1998 Feb 27;124(2):149-55 [9500204.001]
  • [Cites] Int J Mol Med. 1999 May;3(5):531-6 [10202187.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2005 Mar 30;85(12):835-8 [15949402.001]
  • [Cites] Neurosurgery. 1999 May;44(5):1077-82; discussion 1082-3 [10232541.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1721-9 [16452232.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3210-8 [12115353.001]
  • [Cites] J Neurooncol. 2006 Nov;80(2):143-9 [16648987.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9355-62 [16230398.001]
  • [Cites] Int J Cancer. 2006 May 1;118(9):2182-9 [16331629.001]
  • [Cites] Int J Dev Neurosci. 1999 Aug-Oct;17(5-6):517-30 [10571413.001]
  • [Cites] Int J Cancer. 2006 Feb 1;118(3):583-92 [16106403.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6144-52 [17062691.001]
  • [Cites] Front Biosci. 2004 Sep 01;9:3105-23 [15353341.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7443-8 [11416216.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5391-8 [9393765.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4479-86 [15958633.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 15;91(18):1548-56 [10491431.001]
  • [Cites] Neuro Oncol. 2001 Apr;3(2):82-8 [11296484.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):436-51 [16212809.001]
  • [Cites] Int J Cancer. 1999 Feb 19;84(1):10-8 [9988225.001]
  • [Cites] FASEB J. 2002 Jan;16(1):108-10 [11729097.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4578-85 [14555533.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jun 24;273(1):287-93 [10873600.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Jun 27;235(3):743-7 [9207232.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Aug 10;249(1):73-7 [9705834.001]
  • [Cites] Mol Cancer Res. 2008 Jan;6(1):139-50 [18234969.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1292-8 [16489086.001]
  • (PMID = 19856144.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 67256-21-7 / Hepatocyte Growth Factor
  •  go-up   go-down


29. Uematsu M, Ohsawa I, Aokage T, Nishimaki K, Matsumoto K, Takahashi H, Asoh S, Teramoto A, Ohta S: Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index. J Neurooncol; 2005 May;72(3):231-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We prepared polyclonal anti-survivin serum to establish a survivin index for stained sections, using an immunohistochemical procedure, according to the method used for scoring MIB-1 index, and then stained 29 paraffin-embedded sections from surgical specimens of 29 patients who were classified into three grades of World Health Organization with the mean age of low grade astocytoma (grade II) being 34.7; anaplastic astrocytoma (grade III), 48.8; and glioblastoma multiform (grade IV), 58.4.
  • The mean percentage of immunoreactive cells in each specimen was 70.0 (SD 18.2) in grade II, 81.3 (16.5) in grade III, and 85.0 (13.6) in grade IV.
  • Then we compared the survivin index to the MIB-1 index and found that in low-grade gliomas (grade II and III), the difference in survival times between the high and low survivin indexes was significant (P=0.007), whereas that between the high and low MIB-1 indexes was not significant (P=0.092).
  • ONCLUSION: Survivin is more sensitive marker than MIB-1 for the evaluation of low-grade gliomas in that it helps to predict patient survival.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies / analysis. Biomarkers, Tumor. Blotting, Western. Child. DNA, Complementary / genetics. Disease Progression. Female. Humans. Immunohistochemistry. Inhibitor of Apoptosis Proteins. Male. Middle Aged. Neoplasm Proteins. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis. Treatment Outcome. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):996-1001 [11958894.001]
  • [Cites] Cancer Res. 1987 Jul 15;47(14):3847-50 [3594441.001]
  • [Cites] Oncogene. 2000 Feb 3;19(5):617-23 [10698506.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6097-102 [10626797.001]
  • [Cites] J Neurooncol. 1997 Aug;34(1):31-5 [9210051.001]
  • [Cites] Clin Lab Med. 1999 Dec;19(4):833-47 [10572718.001]
  • [Cites] Pathol Oncol Res. 2001;7(4):267-78 [11882906.001]
  • [Cites] Acta Neurochir (Wien). 2002 Feb;144(2):151-5; discussion 155-6 [11862515.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1063-8 [11844831.001]
  • [Cites] J Invest Dermatol. 1999 Sep;113(3):415-8 [10469343.001]
  • [Cites] Nature. 1998 Dec 10;396(6711):580-4 [9859993.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2720-6 [11745208.001]
  • [Cites] J Neurochem. 2001 Oct;79(2):426-36 [11677271.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4364-8 [12154041.001]
  • [Cites] Neurochirurgie. 1998 Mar;44(1):25-30 [9757314.001]
  • [Cites] J Cell Sci. 2002 Feb 1;115(Pt 3):575-85 [11861764.001]
  • [Cites] Mol Hum Reprod. 2000 Jun;6(6):529-34 [10825370.001]
  • [Cites] J Biol Chem. 1998 May 1;273(18):11177-82 [9556606.001]
  • [Cites] Cancer. 2002 Jul 15;95(2):249-57 [12124823.001]
  • [Cites] Oncogene. 1999 Oct 21;18(43):5870-8 [10557074.001]
  • [Cites] Med Electron Microsc. 2001 Dec;34(4):207-12 [11956993.001]
  • [Cites] J Neurooncol. 1999;44(3):255-66 [10720205.001]
  • [Cites] J Exp Clin Cancer Res. 1997 Jun;16(2):153-7 [9261740.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1435-42 [10666222.001]
  • (PMID = 15937645.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / DNA, Complementary; 0 / Inhibitor of Apoptosis Proteins; 0 / Ki-67 Antigen; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


30. Balzarotti M, Fontana F, Marras C, Boiardi A, Croci D, Ciusani E, Salmaggi A: In vitro study of low molecular weight heparin effect on cell growth and cell invasion in primary cell cultures of high-grade gliomas. Oncol Res; 2006;16(5):245-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro study of low molecular weight heparin effect on cell growth and cell invasion in primary cell cultures of high-grade gliomas.
  • In the last years results of preclinical and clinical studies have suggested that LMWH may be able to inhibit cell growth, cell invasion, and angiogenesis, which are key mechanisms involved in tumor progression, possibly influencing favorable clinical outcome in at least a proportion of cancer patients.
  • In this work we investigated the effect of LMWH (enoxaparin) on cell growth and cell invasion in primary cell cultures obtained from high-grade glioma specimens: 5 anaplastic astrocytoma (AA) and 13 glioblastoma multiforme (GBM).
  • A significant decrease in tumor cell growth was observed after treatment with 10 U/ml (-21%; p = 0.001) and 100 U/ml (-26%; p < 0.001); tumor cells from AA (grade III;.
  • WHO) were more affected by LMWH treatment compared to cell lines from GBM (grade IV; WHO).
  • In conclusion, our results confirm the antineoplastic effect of LMWH, suggesting a potential direct role on tumor cell growth in high grade gliomas.
  • [MeSH-minor] Adolescent. Adult. Aged. Apoptosis / drug effects. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Female. Flow Cytometry. Gene Expression Regulation, Neoplastic / drug effects. Gene Expression Regulation, Neoplastic / genetics. Humans. Male. Middle Aged. Molecular Weight. Neoplasm Invasiveness. Receptor, PAR-1 / biosynthesis. Receptor, PAR-1 / drug effects. Receptor, PAR-1 / genetics. Sensitivity and Specificity. Structure-Activity Relationship. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17294805.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enoxaparin; 0 / Receptor, PAR-1
  •  go-up   go-down


31. Zhang L, Yamane T, Satoh E, Amagasaki K, Kawataki T, Asahara T, Furuya K, Nukui H, Naganuma H: Establishment and partial characterization of five malignant glioma cell lines. Neuropathology; 2005 Jun;25(2):136-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Five malignant glioma cell lines (YMG1, 2, 3, 4, and 5) were established from surgical specimens obtained from patients with glioblastoma or anaplastic astrocytoma, and these lines were partially characterized.
  • Immunohistochemical studies revealed that the patterns of p53 and EGFR expressions in the original tumor tissues were mostly correlated with those in the malignant glioma cell lines.
  • These results suggest that the characteristics of p53 and EGFR expression in the malignant glioma cell lines were passed over from the original tumor tissues.
  • These newly established malignant glioma cell lines can be used for further analysis of the mechanisms of tumor growth and progression.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Cell Line, Tumor. Gene Expression. Glioma / metabolism
  • [MeSH-minor] Adult. Aged. Blotting, Western. Cell Cycle Proteins / biosynthesis. Cyclin-Dependent Kinase 4. Cyclin-Dependent Kinase Inhibitor p15. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Cyclin-Dependent Kinases / biosynthesis. Female. Glial Fibrillary Acidic Protein / biosynthesis. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Proto-Oncogene Proteins / biosynthesis. Receptor, Epidermal Growth Factor / biosynthesis. S100 Proteins / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis. Tumor Suppressor Proteins / biosynthesis

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15875906.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN2B protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Glial Fibrillary Acidic Protein; 0 / Proto-Oncogene Proteins; 0 / S100 Proteins; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 2.7.11.22 / Cyclin-Dependent Kinases
  •  go-up   go-down


32. Pogoda JM, Preston-Martin S, Howe G, Lubin F, Mueller BA, Holly EA, Filippini G, Peris-Bonet R, McCredie MR, Cordier S, Choi W: An international case-control study of maternal diet during pregnancy and childhood brain tumor risk: a histology-specific analysis by food group. Ann Epidemiol; 2009 Mar;19(3):148-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An international case-control study of maternal diet during pregnancy and childhood brain tumor risk: a histology-specific analysis by food group.
  • The cured meat association was specific to astrocytomas (odds ratio [OR] range=1.8-2.5 across astrocytoma subtypes for 4th vs. 1st quartile of consumption, p trends <or= 0.03) and ependymomas (OR, 2.0; 95% confidence interval (CI), 0.4-2.9 for 4th vs. 1(st) quartile; p trend=0.03) and was similar in magnitude to previously reported ORs relating maternal cured meat consumption to increased astroglial risk.
  • Other histology-specific associations were decreased risk of anaplastic astrocytomas from cruciferous vegetables (OR, 0.4; 95% CI, 0.3-0.7 for 4th vs. 1st quartile; p trend<0.0001), decreased risk of astroglial tumors from fresh fish (OR, 0.6; 95% CI, 0.5-0.9 for 4th vs. 1st quartile; p trend=0.008), and increased risk of medulloblastoma from oil products (OR, 1.5; 95% CI, 1.0-2.2 for 4th vs. 1(st) quartile; p trend=0.005).
  • CONCLUSIONS: These results suggest the need for dietary analysis not only by brain tumor histology, but also by specific foods within a broad food group.

  • Genetic Alliance. consumer health - Pregnancy.
  • Genetic Alliance. consumer health - Brain Tumor, Childhood.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Epidemiol. 2001 Dec 15;154(12):1136-42 [11744519.001]
  • [Cites] Med Pediatr Oncol. 2001 Feb;36(2):274-82 [11452935.001]
  • [Cites] J Neurooncol. 2002 Oct;60(1):61-9 [12416547.001]
  • [Cites] Mutat Res. 2004 Nov 2;555(1-2):173-90 [15476859.001]
  • [Cites] Z Krebsforsch. 1968;71(4):320-60 [4237278.001]
  • [Cites] Proc Natl Acad Sci U S A. 1974 Mar;71(3):639-43 [4522778.001]
  • [Cites] J Am Diet Assoc. 1979 Dec;75(6):647-65 [389993.001]
  • [Cites] IARC Sci Publ. 1980;(32):5-338 [7216345.001]
  • [Cites] Arch Geschwulstforsch. 1981;51(2):187-203 [7271429.001]
  • [Cites] Ann N Y Acad Sci. 1982;381:274-89 [6953795.001]
  • [Cites] Cancer Res. 1982 Dec;42(12):5240-5 [7139628.001]
  • [Cites] Recent Results Cancer Res. 1983;84:63-76 [6844702.001]
  • [Cites] IARC Sci Publ. 1983;(51):65-79 [6365774.001]
  • [Cites] Am J Epidemiol. 1985 Nov;122(5):904-14 [4050778.001]
  • [Cites] Biometrics. 1986 Mar;42(1):121-30 [3719049.001]
  • [Cites] IARC Sci Publ. 1989;(96):17-34 [2553598.001]
  • [Cites] Cancer Res. 1990 May 1;50(9):2608-12 [2328486.001]
  • [Cites] Br J Neurosurg. 1990;4(1):17-25 [2334522.001]
  • [Cites] In Vivo. 1990 Sep-Oct;4(5):327-35 [2133106.001]
  • [Cites] N Engl J Med. 1993 Aug 19;329(8):536-41 [8336753.001]
  • [Cites] Int J Cancer. 1994 Jan 2;56(1):11-5 [8262665.001]
  • [Cites] Cancer Causes Control. 1994 Mar;5(2):141-8 [8167261.001]
  • [Cites] Cancer Causes Control. 1994 Mar;5(2):177-87 [8167265.001]
  • [Cites] Int J Cancer. 1994 Jun 15;57(6):769-74 [8206670.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Apr-May;3(3):197-204 [8019366.001]
  • [Cites] Int J Cancer. 1994 Dec 15;59(6):776-82 [7989118.001]
  • [Cites] Cancer Lett. 1995 Jun 29;93(1):17-48 [7600541.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):6941-6 [8692923.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Aug;5(8):599-605 [8824361.001]
  • [Cites] Am J Clin Nutr. 1997 Apr;65(4 Suppl):1153S-1158S [9094913.001]
  • [Cites] Cancer Causes Control. 1997 Sep;8(5):688-97 [9328190.001]
  • [Cites] Environ Health Perspect. 1998 Jun;106 Suppl 3:887-92 [9646053.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Jul;7(7):635-8 [9681534.001]
  • [Cites] Biometrics. 1998 Sep;54(3):948-63 [9750244.001]
  • [Cites] Pediatr Neurol. 1999 Mar;20(3):198-203 [10207928.001]
  • [Cites] Cancer. 1999 May 1;85(9):2077-90 [10223251.001]
  • [Cites] Cancer Causes Control. 2005 Aug;16(6):619-35 [16049800.001]
  • [Cites] Cancer Causes Control. 2005 Sep;16(7):877-91 [16132798.001]
  • [Cites] Ann Epidemiol. 2009 Mar;19(3):161-71 [19216998.001]
  • [Cites] Am J Epidemiol. 1986 Oct;124(4):595-602 [3752053.001]
  • [Cites] Int J Cancer. 2000 Apr 1;86(1):139-43 [10728608.001]
  • [Cites] Carcinogenesis. 2000 Jun;21(6):1157-62 [10837004.001]
  • [Cites] Pediatr Neurosurg. 2000 Jun;32(6):321-6 [10971194.001]
  • [Cites] Int J Epidemiol. 2001 Apr;30(2):317-9 [11369736.001]
  • [Cites] J Pediatr Endocrinol Metab. 2002 May;15 Suppl 2:669-73 [12092679.001]
  • (PMID = 19216997.001).
  • [ISSN] 1873-2585
  • [Journal-full-title] Annals of epidemiology
  • [ISO-abbreviation] Ann Epidemiol
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES007048; United States / NCI NIH HHS / CA / P01 CA017054-30; United States / NCI NIH HHS / PC / N01 PC035139; United States / NCI NIH HHS / CA / CA47082; United States / NIEHS NIH HHS / ES / P30 ES007048-029003; United States / NCI NIH HHS / CA / CA47081; United States / NCI NIH HHS / CA / CA17054; United States / NCI NIH HHS / CN / N01-CN-05230; United States / NIEHS NIH HHS / ES / ES007048-029003; United States / NCI NIH HHS / CN / N01-CN-25403; United States / NCI NIH HHS / CA / P01 CA017054; United States / NCI NIH HHS / CA / N01 CN025403; United States / NCI NIH HHS / CN / N01 CN005230; United States / NIEHS NIH HHS / ES / 5P30 ES07048
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nitroso Compounds
  • [Other-IDs] NLM/ NIHMS98974; NLM/ PMC2832584
  •  go-up   go-down


33. Tehrani M, Friedman TM, Olson JJ, Brat DJ: Intravascular thrombosis in central nervous system malignancies: a potential role in astrocytoma progression to glioblastoma. Brain Pathol; 2008 Apr;18(2):164-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravascular thrombosis in central nervous system malignancies: a potential role in astrocytoma progression to glioblastoma.
  • Intravascular thrombosis is a frequent finding in glioblastoma [GBM; World Health Organization (WHO) grade IV] specimens and could potentially be involved in astrocytoma progression to GBM or represent a surrogate marker of GBM histology.
  • We investigated whether intravascular thrombosis was more frequent or prominent in GBM than other central nervous system (CNS) malignancies and considered its prognostic significance in anaplastic astrocytoma (AA; WHO grade III), which lacks necrosis.
  • Histologic sections were examined for thrombosis, necrosis and microvascular hyperplasia from each of 297 CNS tumors, including 103 GBMs, 46 AAs, 20 diffuse astrocytoma (DAs; WHO grade II), eight anaplastic oligodendrogliomas (AOs; WHO grade III), 20 oligodendrogliomas (ODs; WHO grade II), 49 metastatic carcinomas (METs), 31 primary central nervous system lymphomas (PCNSLs) and 20 medulloblastomas (MBs).

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2584-91 [16510576.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jun;65(6):529-39 [16783163.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Sep;65(9):846-54 [16957578.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10643-6 [17108099.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 May;62(2):126-36 [17293122.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Proc Staff Meet Mayo Clin. 1949 Feb 2;24(3):71-5 [18111063.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2606-18 [10861440.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Mar;60(3):248-62 [11245209.001]
  • [Cites] Thromb Res. 2001 Jun 15;102(6):V215-24 [11516455.001]
  • [Cites] Curr Opin Pulm Med. 2001 Sep;7(5):326-31 [11584184.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):480-6 [1899696.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):845-8 [1279432.001]
  • [Cites] Neurosurgery. 1995 Feb;36(2):375-80; discussion 380-1 [7731519.001]
  • [Cites] Cancer. 1996 Mar 15;77(6):1161-6 [8635139.001]
  • [Cites] Noshuyo Byori. 1996 Nov;13(2):115-8 [8958516.001]
  • [Cites] J Pathol Bacteriol. 1954 Jul;68(1):231-3 [13212575.001]
  • [Cites] Acta Pathol Microbiol Scand. 1950;27(1):51-64 [15406242.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1406-13 [15735028.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):122-33 [15831231.001]
  • [Cites] Trends Mol Med. 2002;8(4 Suppl):S62-7 [11927290.001]
  • [Cites] Clin Biochem. 2002 Jun;35(4):321-5 [12135696.001]
  • [Cites] Neurosurgery. 2002 Jul;51(1):2-12; discussion 12-3 [12182418.001]
  • [Cites] Ann Intern Med. 2003 Apr 15;138(8):659-68 [12693889.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):920-7 [14871821.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1147-52 [15001257.001]
  • [Cites] Lab Invest. 2004 Apr;84(4):397-405 [14990981.001]
  • [Cites] Cancer. 1983 Aug 1;52(3):550-4 [6305479.001]
  • [Cites] Cancer. 1987 May 1;59(9):1617-25 [3030531.001]
  • [Cites] Cancer. 1988 Nov 15;62(10):2152-65 [3179928.001]
  • (PMID = 18093251.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS053727-01; United States / NINDS NIH HHS / NS / R01 NS053727; United States / NINDS NIH HHS / NS / NS053727; United States / NINDS NIH HHS / NS / R01 NS053727-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ NIHMS82090; NLM/ PMC2610479
  •  go-up   go-down


34. Volavsek M, Lamovec J, Popović M: Extraneural metastases of anaplastic oligodendroglial tumors. Pathol Res Pract; 2009;205(7):502-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraneural metastases of anaplastic oligodendroglial tumors.
  • According to the literature, they tend to appear in glioblastoma patients, but are exceptionally rare in anaplastic oligodendroglioma.
  • We report on an anaplastic oligodendroglioma and an anaplastic oligoastrocytoma that metastasized to cervical lymph nodes and bones.
  • Fine needle aspiration biopsy (FNAB) of the cervical lymph node prior to neck dissection suggested a possible metastatic primitive neuroepithelial tumor.
  • In the second case, metastases to the sacrum and femur developed after surgery for a recurrent anaplastic oligoastrocytoma.
  • Our two cases reconfirm a rare but definite ability not only of glioblastoma but also of anaplastic oligodendroglioma, namely to metastasize to extraneural sites.
  • It is important to bear this in mind, particularly in cases when the history of primary brain tumor is unavailable.
  • [MeSH-major] Astrocytoma / secondary. Brain Neoplasms / pathology. Femoral Neoplasms / secondary. Neoplasm Recurrence, Local. Oligodendroglia / pathology. Oligodendroglioma / secondary. Sacrum / pathology. Spinal Neoplasms / secondary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols. Chemotherapy, Adjuvant. Cranial Irradiation. Craniotomy. Fatal Outcome. Female. Humans. Lymphatic Metastasis. Middle Aged. Radiotherapy, Adjuvant. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19410385.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


35. Dutta D, Vanere P, Gupta T, Munshi A, Jalali R: Factors influencing activities of daily living using FIM-FAM scoring system before starting adjuvant treatment in patients with brain tumors: results from a prospective study. J Neurooncol; 2009 Aug;94(1):103-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Patients with brain tumors have varied degree of functional and psychological impairments because of factors relating to the tumor or to the treatment they receive.
  • MATERIAL AND METHOD: From August 2007 to April 2008, 150 consecutive adult (>18 years) primary brain tumor patients (median age 40 years; male 88, female 62) registered in a general out-patient neuro-oncology clinic were accrued and detailed data were recorded.
  • Seventy percent had malignant tumor (66% high-grade and 34% low-grade; 70% intra-axial).
  • Glioblastoma (GBM) (23.3%), anaplastic astrocytoma (AA) (18.7%), and diffuse fibrillary astrocytoma (18.7%) were the commonest histologic subtypes.
  • Univariate analysis showed total FIM-FAM scores not significantly different with age (< or =35 years vs. >35 years; P = 0.994), sex (male versus female; P = 0.133), and grade of the tumor (high-grade versus low-grade; P = 0.142) but were significantly higher in patients with a Karnofsky performance score (KPS) of > or =70 as compared with <70 (P = 0.001), neurological performance scale (NPS) of 0 or 1 vs. 2 or 3; P = 0.001), disease type (benign versus malignant; P = 0.001), and site of disease (cerebral versus cerebellar; P = 0.024).
  • A trend for correlation between tumor sites with the corresponding function as assesses on the FIM-FAM score was observed.
  • There is strong correlation with age, type of tumor, and site of disease with different functional and cognitive domain impairment.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Analysis of Variance. Female. Humans. Male. Middle Aged. Prospective Studies. Psychometrics. Retrospective Studies. Severity of Illness Index. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Stress.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Oncol (R Coll Radiol). 2000;12(1):36-41 [10749018.001]
  • [Cites] J Neurooncol. 2008 Mar;87(1):111-4 [18004503.001]
  • [Cites] Disabil Rehabil. 2004 Feb 18;26(4):235-45 [15164957.001]
  • [Cites] Spinal Cord. 1997 Jan;35(1):22-5 [9025215.001]
  • [Cites] Arch Phys Med Rehabil. 1993 Jun;74(6):566-73 [8503745.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1999 Apr;66(4):480-4 [10201420.001]
  • [Cites] J Neurooncol. 1997 Sep;34(2):187-92 [9210067.001]
  • [Cites] J Neurooncol. 2008 Dec;90(3):321-8 [18704269.001]
  • [Cites] Paraplegia. 1993 Jul;31(7):457-61 [8371936.001]
  • [Cites] Am J Phys Med Rehabil. 1993 Apr;72(2):84-9 [8476548.001]
  • [Cites] Disabil Rehabil. 1995 Jan;17(1):10-4 [7858276.001]
  • [Cites] Scand J Caring Sci. 1990;4(3):99-106 [2120762.001]
  • [Cites] Arch Phys Med Rehabil. 2001 Nov;82(11):1540-6 [11689973.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):646-50 [10653880.001]
  • [Cites] J Clin Oncol. 1984 Mar;2(3):187-93 [6699671.001]
  • [Cites] J Neurol. 2008 Jun;255(6):820-7 [18500499.001]
  • (PMID = 19255726.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


36. Kikuchi T, Kumabe T, Higano S, Watanabe M, Tominaga T: Minimum apparent diffusion coefficient for the differential diagnosis of ganglioglioma. Neurol Res; 2009 Dec;31(10):1102-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The minimum ADC (minADC) of each tumor was pre-operatively determined from several regions of interest.
  • The minADC of ganglioglioma was compared with that of low- or high-grade astrocytomas (astrocytoma, anaplastic astrocytoma and glioblastoma).
  • Tumor cellularity of gangliogliomas was compared with the minADC.
  • RESULTS: The mean minADC of the gangliogliomas (1.45 +/- 0.20 x 10(-3) mm(2)/s) was significantly higher than that of the low- or high-grade astrocytomas.
  • Tumor cellularity of ganglioglioma was inversely correlated with the minADC value.
  • DISCUSSION: The minADC value reflects in the low tumor cellularity of gangliogliomas and may provide a method for the differential diagnosis of ganglioglioma.
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / diagnosis. Astrocytoma / pathology. Brain / pathology. Diagnosis, Differential. Female. Humans. Image Processing, Computer-Assisted. Male. Middle Aged

  • Genetic Alliance. consumer health - Ganglioglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19138470.001).
  • [ISSN] 1743-1328
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


37. Comincini S, Ferrara V, Arias A, Malovini A, Azzalin A, Ferretti L, Benericetti E, Cardarelli M, Gerosa M, Passarin MG, Turazzi S, Bellazzi R: Diagnostic value of PRND gene expression profiles in astrocytomas: relationship to tumor grades of malignancy. Oncol Rep; 2007 May;17(5):989-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of PRND gene expression profiles in astrocytomas: relationship to tumor grades of malignancy.
  • It is abundant in testis and, unlike PRNP, it is expressed at low levels in the adult central nervous system (CNS).
  • Recently, ectopic expression of doppel was found in two different tumor types, specifically in glial and haematological cancers.
  • In order to address clinical important issues, PRND mRNA expression was investigated in a panel of 111 astrocytoma tissue samples, histologically classified according to the World Health Organization (WHO) criteria (6 grade I pilocytic astrocytomas, 15 grade II low-grade astrocytomas, 26 grade III anaplastic astrocytomas and 64 grade IV glioblastoma multiforme).
  • Real-time PRND gene expression profiling, after normalisation with GAPDH, revealed large differences between low (WHO I and II) and high grade (III and IV) of malignancy (P<0.001).
  • Extensive differences in PRND gene expression were also found within each grade of malignancy, suggesting that PRND mRNA quantitation might be useful to distinguish astrocytoma subtypes, and important in disease stratification and in the assessment of specific treatment strategies.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Prions / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Algorithms. Child. Cluster Analysis. Female. GPI-Linked Proteins. Gene Expression Profiling. Glioblastoma / genetics. Glioblastoma / metabolism. Glioblastoma / pathology. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17390034.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / PRND protein, human; 0 / Prions
  •  go-up   go-down


38. Fayed N, Modrego PJ: The contribution of magnetic resonance spectroscopy and echoplanar perfusion-weighted MRI in the initial assessment of brain tumours. J Neurooncol; 2005 May;72(3):261-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We included 55 patients diagnosed with single brain tumour by CT and MRI, and final histopathological verification of the tumour type: 25 were low-grade gliomas, 8 anaplastic gliomas, 11 glioblastomas, and 11 solitary metastases.
  • In MRS, we found significant differences in Choline/Creatine ratios in relation to the tumour type with the highest values in high-grade gliomas and metastases.
  • The mean rCBV was 1.24 for benign tumours and 1.5 for the malignant ones(1.24 for low-grade gliomas, 1.91 for anaplastic gliomas, 1.03 for glioblastomas, and 1.57 for metastases).
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / chemistry. Astrocytoma / diagnosis. Astrocytoma / pathology. Blood Volume / physiology. Child. Child, Preschool. Choline / metabolism. Creatine / metabolism. Creatinine / metabolism. Female. Glioma / chemistry. Glioma / diagnosis. Glioma / pathology. Humans. Lactates / metabolism. Male. Middle Aged. Neoplasm Metastasis / diagnosis. ROC Curve. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. CREATINE .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2004 Feb;25(2):214-21 [14970020.001]
  • [Cites] Acad Radiol. 2001 May;8(5):384-91 [11345268.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Feb;24(2):225-33 [12591638.001]
  • [Cites] AJR Am J Roentgenol. 2002 Sep;179(3):783-9 [12185064.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Feb;21(2):357-66 [10696024.001]
  • [Cites] AJR Am J Roentgenol. 1998 Dec;171(6):1479-86 [9843274.001]
  • [Cites] Br J Neurosurg. 2002 Aug;16(4):329-34 [12389884.001]
  • [Cites] Magn Reson Med. 2003 Feb;49(2):223-32 [12541241.001]
  • [Cites] Neurosci Lett. 2003 May 22;342(3):163-6 [12757890.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Oct;21(9):1645-9 [11039343.001]
  • [Cites] Radiology. 2002 Mar;222(3):715-21 [11867790.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 May;25(5):746-55 [15140713.001]
  • [Cites] Clin Radiol. 2004 Jan;59(1):77-85 [14697379.001]
  • [Cites] Neuroimaging Clin N Am. 2002 Nov;12(4):599-613 [12687914.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98 [14625221.001]
  • [Cites] Eur Radiol. 2003 Mar;13(3):582-91 [12594562.001]
  • [Cites] Neuroradiology. 2002 May;44(5):371-81 [12012120.001]
  • [Cites] Neurosurgery. 2001 Oct;49(4):823-9 [11564242.001]
  • [Cites] Invest Radiol. 1999 Mar;34(3):230-5 [10084669.001]
  • [Cites] Radiology. 1999 Jun;211(3):791-8 [10352608.001]
  • (PMID = 15937650.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lactates; AYI8EX34EU / Creatinine; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


39. Inagawa H, Ishizawa K, Hirose T: Qualitative and quantitative analysis of cytologic assessment of astrocytoma, oligodendroglioma and oligoastrocytoma. Acta Cytol; 2007 Nov-Dec;51(6):900-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Qualitative and quantitative analysis of cytologic assessment of astrocytoma, oligodendroglioma and oligoastrocytoma.
  • OBJECTIVE: To evaluate the usefulness of intraoperative cytology for differential diagnoses of astrocytoma, oligodendroglioma and oligoastrocytoma.
  • In addition, we attempted a computer-assisted image analysis of tumor cell nuclei and compared the results with qualitative observations.
  • In both tumors of a higher grade, anaplastic large nuclei and proliferating endothelial cells were noted.
  • CONCLUSION; Cytologic evaluation using touch or squash preparations is of great help for intraoperative differential diagnosis of astrocytoma, oligodendroglioma and oligoastrocytoma.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Cytodiagnosis / methods. Oligodendroglioma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Count. Cell Nucleus / pathology. Child. Child, Preschool. Cytoplasm / pathology. Diagnosis, Differential. Female. Humans. Image Processing, Computer-Assisted. Intraoperative Period. Male. Middle Aged


40. Calli C, Kitis O, Yunten N, Yurtseven T, Islekel S, Akalin T: Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors. Eur J Radiol; 2006 Jun;58(3):394-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Common contrast-enhancing malignant tumors of the brain are glioblastoma multiforme (GBMs), anaplastic astrocytomas (AAs), metastases, and lymphomas, all of which have sometimes similar conventional MRI findings.
  • Minimum ADC values (ADC(min)) of each tumor was later calculated from ADC map images.
  • PWI was applied using dynamic susceptibility contrast technique and maximum relative cerebral blood volume (rCBV(max)) was calculated from each tumor, given in ratio with contralateral normal white matter.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Diffusion Magnetic Resonance Imaging / methods. Glioblastoma / diagnosis. Image Enhancement / methods. Lymphoma / diagnosis. Magnetic Resonance Angiography / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Blood Volume / physiology. Cerebrovascular Circulation / physiology. Child. Contrast Media / administration & dosage. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527438.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


41. Reardon DA, Quinn JA, Vredenburgh J, Rich JN, Gururangan S, Badruddoja M, Herndon JE 2nd, Dowell JM, Friedman AH, Friedman HS: Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer; 2005 Jan 15;103(2):329-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Thirty-four of the 37 patients enrolled in the current study (92%) were diagnosed with recurrent GBM and 3 patients (8%) were diagnosed with recurrent anaplastic astrocytoma (AA).
  • Hematologic toxicities of >/= Grade 3 (according the second version of the Common Toxicity Criteria of the National Cancer Institute) reportedly complicated 8.6% of treatment courses.
  • Grade 3 diarrhea, the most commonly reported nonhematologic toxicity, occurred with equal frequency (8%), regardless of whether the patient was receiving EIAED.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / drug therapy. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Pyrazoles / administration & dosage. Sulfonamides / administration & dosage
  • [MeSH-minor] Adult. Aged. Biological Availability. Celecoxib. Confidence Intervals. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Magnetic Resonance Imaging. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Probability. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15558802.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 P20 CA096890; United States / NCI NIH HHS / CA / CA11898; United States / NCRR NIH HHS / RR / M01 RR 30; United States / NINDS NIH HHS / NS / NS20023
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pyrazoles; 0 / Sulfonamides; 7673326042 / irinotecan; JCX84Q7J1L / Celecoxib; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


42. Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Wong TZ, Bigner DD: Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med; 2008 Jan;49(1):30-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.
  • alpha-Particle-emitting radionuclides, such as (211)At, with a 7.2-h half-life, may be optimally suited for the molecularly targeted radiotherapy of strategically sensitive tumor sites, such as those in the central nervous system.
  • Because of the much shorter range and more potent cytotoxicity of alpha-particles than of beta-particles, (211)At-labeled agents may be ideal for the eradication of tumor cells remaining after surgical debulking of malignant brain tumors.
  • Six patients experienced grade 2 neurotoxicity within 6 wk of (211)At-ch81C6 administration; this neurotoxicity resolved fully in all but 1 patient.
  • No toxicities of grade 3 or higher were attributable to the treatment.
  • The median survival times for all patients, those with glioblastoma multiforme, and those with anaplastic astrocytoma or oligodendroglioma were 54, 52, and 116 wk, respectively.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunother. 1997 May;20(3):214-43 [9181460.001]
  • [Cites] Appl Radiat Isot. 1996 Feb;47(2):135-43 [8852627.001]
  • [Cites] Radiat Res. 1998 Feb;149(2):155-62 [9457895.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2202-12 [9626222.001]
  • [Cites] Nucl Med Biol. 1998 May;25(4):351-7 [9639296.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1933-40 [9731050.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2495-502 [9796983.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):491-9 [10487576.001]
  • [Cites] J Nucl Med. 2005 Jan;46 Suppl 1:199S-204S [15653670.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] J Nucl Med. 2005 Jun;46(6):1042-51 [15937318.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4451-9 [15958630.001]
  • [Cites] J Nucl Med. 2005 Aug;46(8):1393-400 [16085599.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):115-22 [16382120.001]
  • [Cites] J Nucl Med. 2006 Jun;47(6):912-8 [16741299.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10 Suppl):3275s-3280s [10541375.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Curr Pharm Des. 2000 Sep;6(14):1433-55 [10903402.001]
  • [Cites] J Nucl Med. 2001 Oct;42(10):1508-15 [11585865.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1389-97 [11870184.001]
  • [Cites] Int J Cancer. 2002 Mar 20;98(3):362-9 [11920587.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1233-9 [12149203.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):1259-75 [12419456.001]
  • [Cites] Cancer Res. 1983 Jun;43(6):2796-805 [6342760.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Nov;13(11):1767-73 [3667382.001]
  • [Cites] Cancer Res. 1989 May 15;49(10):2807-13 [2469537.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(1):55-7 [1512163.001]
  • [Cites] Invest Radiol. 1993 Jun;28(6):488-96 [7686539.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] Nucl Med Biol. 1996 May;23(4):449-58 [8832699.001]
  • [Cites] Nucl Med Biol. 1997 Apr;24(3):255-61 [9228660.001]
  • (PMID = 18077533.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA108786; United States / NINDS NIH HHS / NS / NS20023; United States / NINDS NIH HHS / NS / P50 NS020023; United States / NCI NIH HHS / CA / R01 CA042324; United States / NINDS NIH HHS / NS / P50 NS020023-268624; United States / NCI NIH HHS / CA / CA014236-35S59008; United States / NCI NIH HHS / CA / CA108786; United States / NCI NIH HHS / CA / CA42324; United States / NCI NIH HHS / CA / CA11898; United States / NCRR NIH HHS / RR / M01 RR30; United States / NINDS NIH HHS / NS / NS020023-268624; United States / NCI NIH HHS / CA / R37 CA042324; United States / NCI NIH HHS / CA / P30 CA014236; United States / NCI NIH HHS / CA / R37 CA042324-23; United States / NCI NIH HHS / CA / P30 CA014236-35S59008; United States / NCI NIH HHS / CA / R37 CA011898
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Radioisotopes; 0 / Radiopharmaceuticals; 0 / Tenascin; XI595HAL7H / Astatine
  • [Other-IDs] NLM/ NIHMS180689; NLM/ PMC2832604
  •  go-up   go-down


43. Brandes AA, Nicolardi L, Tosoni A, Gardiman M, Iuzzolino P, Ghimenton C, Reni M, Rotilio A, Sotti G, Ermani M: Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro Oncol; 2006 Jul;8(3):253-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma.
  • We compared survival in patients with anaplastic astrocytoma (AA) treated with adjuvant procarbazine, lomustine, and vincristine (PCV) with survival in patients treated with temozolomide.
  • [MeSH-major] Adjuvants, Pharmaceutic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Astrocytoma / drug therapy. Astrocytoma / mortality. Dacarbazine / analogs & derivatives
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Lomustine / administration & dosage. Male. Middle Aged. Procarbazine / administration & dosage. Retrospective Studies. Survival Rate. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2004 Oct;31(5):618-34 [15497115.001]
  • [Cites] Semin Oncol. 2003 Dec;30(6 Suppl 19):10-4 [14765378.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):911-4 [9276354.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1468-77 [16088966.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3389-95 [10550132.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2762-71 [10561351.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1109-15 [10613302.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):509-18 [11208845.001]
  • [Cites] Br J Cancer. 2002 Feb 12;86(4):501-5 [11870527.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1063-71 [12569607.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):981-90 [12631596.001]
  • [Cites] J Neurosurg. 2003 Sep;99(3):467-73 [12959431.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4 [2154418.001]
  • (PMID = 16723632.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Pharmaceutic; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; PCV protocol
  • [Other-IDs] NLM/ PMC1871946
  •  go-up   go-down


44. Chamberlain MC, Wei-Tsao DD, Blumenthal DT, Glantz MJ: Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma. Cancer; 2008 May 1;112(9):2038-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma.
  • BACKGROUND: The primary objective of this prospective phase 2 study of CPT-11 in adult patients with recurrent temozolomide-refractory anaplastic astrocytoma (AA) was to evaluate 6-month progression-free survival (PFS).
  • The median time to tumor progression was 4.1 month.
  • CONCLUSIONS: CPT-11 demonstrated modest efficacy with acceptable toxicity in this cohort of adult patients with recurrent AA, all of whom had failed on prior temozolomide chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Prospective Studies

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18361434.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7673326042 / irinotecan; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


45. Hughes MA, Parisi M, Grossman S, Kleinberg L: Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection. Int J Radiat Oncol Biol Phys; 2005 Aug 1;62(5):1423-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND MATERIALS: CD4 counts were measured during RT in 70 of 76 consecutive patients with newly diagnosed Grade III and IV astrocytoma and anaplastic oligodendroglioma treated with corticosteroids and seen at the Johns Hopkins Hospital.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. CD4 Lymphocyte Count. Combined Modality Therapy. Female. Glioblastoma / drug therapy. Glioblastoma / immunology. Glioblastoma / radiotherapy. Humans. Infection. Male. Middle Aged. Radiotherapy, Conformal

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029802.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


46. De Sio L, Milano GM, Castellano A, Jenkner A, Fidani P, Dominici C, Donfrancesco A: Temozolomide in resistant or relapsed pediatric solid tumors. Pediatr Blood Cancer; 2006 Jul;47(1):30-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor types were: neuroblastoma (NB; n = 17), medulloblastoma (MB; 8), brain stem glioma (BSG; 8), extraosseous Ewing's sarcoma/peripheral neuroectodermal tumor (EOES; 4), Ewing's sarcoma (ES; 4), anaplastic astrocytoma (AA; 3), rhabdomyosarcoma (RMS; 2), ependymoma (EP; 2), cerebral primitive neuroectodermal tumor (cPNET; 2), hepatocarcinoma (HC; 1), and osteosarcoma (OS; 1).
  • Haematological toxicity grade 3-4 (mainly thrombocytopenia) was observed in 21.4% of administered courses, nausea was reported in 3.1% and respiratory distress in 0.7%.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / analogs & derivatives. Drug Resistance, Neoplasm. Neoplasm Recurrence, Local / drug therapy. Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Humans. Male. Survival Analysis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • [ErratumIn] Pediatr Blood Cancer. 2006 Oct 15;47(5):647-8
  • (PMID = 16047361.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


47. Khan MK, Hunter GK, Vogelbaum M, Suh JH, Chao ST: Evidence-based adjuvant therapy for gliomas: current concepts and newer developments. Indian J Cancer; 2009 Apr-Jun;46(2):96-107
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 18,820 new cases of primary central nervous system (CNS) tumors diagnosed annually in the United States, gliomas account for over 60% with 30-40% of them being glioblastoma multiforme (GBM), 10% being anaplastic astrocytoma (AA), and 10% being low grade gliomas (LGGs).
  • Of all adult primary CNS tumors, GBM is the most common and the most malignant with about 7,000 to 8,000 new cases annually in the United States.
  • Common to these approaches is the use of adjuvant radiation therapy, even as surgery alone, with or without chemotherapy, may be the mainstay for some lower grade and low-risk gliomas.
  • Specifically, the database is searched using the following keywords, with various combinations: glioma, low-grade, anaplastic, astrocytoma, oligodendroglioma, oligoastrocytoma, glioblastoma multiforme, chemotherapy, radiation, new concepts, phase III, MGMT, CDX-110 (Celldex), temozolomide, 1p/19q deletion, and bevacizumab.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Astrocytoma / therapy. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Glioblastoma / therapy. Humans

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19346643.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 64
  •  go-up   go-down


48. Franceschi E, Omuro AM, Lassman AB, Demopoulos A, Nolan C, Abrey LE: Salvage temozolomide for prior temozolomide responders. Cancer; 2005 Dec 1;104(11):2473-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The median age of the patients was 56 years (range, 25-67 yrs) at the time of diagnosis; 9 patients had glioblastoma, 3 had anaplastic astrocytoma, and 2 patients had low-grade oligodendroglioma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy. Oligodendroglioma / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Recurrence. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270316.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


49. Yanni DS, Ulkatan S, Deletis V, Barrenechea IJ, Sen C, Perin NI: Utility of neurophysiological monitoring using dorsal column mapping in intramedullary spinal cord surgery. J Neurosurg Spine; 2010 Jun;12(6):623-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 4 ependymomas, 1 subependymoma, 1 gangliocytoma, 1 anaplastic astrocytoma, 1 cavernous malformation, and 2 symptomatic syringes requiring shunting.
  • [MeSH-minor] Adult. Aged. Electrodes. Ependymoma / surgery. Evoked Potentials, Motor / physiology. Female. Humans. Male. Middle Aged. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20515347.001).
  • [ISSN] 1547-5646
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Okada H, Lieberman FS, Walter KA, Lunsford LD, Kondziolka DS, Bejjani GK, Hamilton RL, Torres-Trejo A, Kalinski P, Cai Q, Mabold JL, Edington HD, Butterfield LH, Whiteside TL, Potter DM, Schold SC Jr, Pollack IF: Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med; 2007;5:67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In University of Pittsburgh Cancer Institute (UPCI) protocol 95-033, adult participants with recurrent glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA) received gross total resection (GTR) of the recurrent tumors, followed by two vaccinations with autologous fibroblasts retrovirally transfected with TFG-IL4-Neo-TK vector admixed with irradiated autologous glioma cells.
  • In UPCI 99-111, adult participants with newly diagnosed GBM or AA, following GTR and radiation therapy, received two intradermal vaccinations with the TFG-IL4-Neo-TK-transfected fibroblasts admixed with type-1 dendritic cells (DC) loaded with autologous tumor lysate.
  • Four other participants were withdrawn from the trial because of tumor progression prior to production of the cellular vaccine.
  • Moreover, both participants demonstrated clinical and radiological improvement with no evidence of allergic encephalitis, although both participants eventually succumbed with the tumor recurrence.
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Feasibility Studies. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2005 Jun 1;174(11):7194-201 [15905564.001]
  • [Cites] Gene Ther. 2005 May;12(9):733-41 [15772692.001]
  • [Cites] Neoplasia. 2005 Aug;7(8):717-22 [16207473.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5883-91 [16740728.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4478-87 [16618775.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):709-18 [16481638.001]
  • [Cites] J Transl Med. 2007;5:10 [17295916.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6451-8 [17616706.001]
  • [Cites] Hum Gene Ther. 2000 Mar 1;11(4):637-53 [10724042.001]
  • [Cites] Cancer Gene Ther. 2000 Mar;7(3):486-94 [10766355.001]
  • [Cites] J Immunol. 2000 Aug 15;165(4):1877-81 [10925267.001]
  • [Cites] J Exp Med. 2000 Sep 18;192(6):823-33 [10993913.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):842-7 [11221866.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1848-54 [11251017.001]
  • [Cites] Hum Gene Ther. 2001 Mar 20;12(5):575-95 [11268289.001]
  • [Cites] Gene Ther. 2001 Aug;8(15):1157-66 [11509946.001]
  • [Cites] Nat Immunol. 2001 Nov;2(11):1054-60 [11600887.001]
  • [Cites] Brain Res Brain Res Rev. 2003 May;42(2):97-122 [12738053.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3188-92 [12789295.001]
  • [Cites] Blood. 2003 Jul 1;102(1):36-42 [12560234.001]
  • [Cites] J Neurooncol. 2003 Aug-Sep;64(1-2):13-20 [12952282.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3826-35 [14551301.001]
  • [Cites] Curr Neurol Neurosci Rep. 2004 May;4(3):218-27 [15102348.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4973-9 [15256471.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5934-7 [15342370.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539-43 [8097319.001]
  • [Cites] Hum Gene Ther. 1994 Jan;5(1):41-55 [8155771.001]
  • [Cites] J Immunother Emphasis Tumor Immunol. 1995 May;17(4):238-48 [7582260.001]
  • [Cites] Hum Gene Ther. 1996 Mar 1;7(4):479-87 [8800742.001]
  • [Cites] Neurosurgery. 1996 Jun;38(6):1096-103; discussion 1103-4 [8727138.001]
  • [Cites] J Invest Dermatol. 1998 May;110(5):762-6 [9579542.001]
  • [Cites] Forum (Genova). 1998 Oct-Dec;8(4):357-64 [9863030.001]
  • [Cites] Science. 1999 Feb 19;283(5405):1183-6 [10024247.001]
  • [Cites] Gene Ther. 1999 Feb;6(2):219-26 [10435106.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5515-25 [16061868.001]
  • (PMID = 18093335.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR000005
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cancer Vaccines; 207137-56-2 / Interleukin-4
  • [Other-IDs] NLM/ PMC2254376
  •  go-up   go-down


51. Lymbouridou R, Soufla G, Chatzinikola AM, Vakis A, Spandidos DA: Down-regulation of K-ras and H-ras in human brain gliomas. Eur J Cancer; 2009 May;45(7):1294-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated the mutational, mRNA and protein expression profile of the ras genes in 21 glioblastomas multiforme (grade IV), four fibrillary astrocytoma (grade II), four anaplastic astrocytoma (grade III) and 15 normal specimens.
  • [MeSH-minor] Adult. Aged. Astrocytoma / genetics. Astrocytoma / metabolism. Astrocytoma / mortality. Blotting, Western / methods. Case-Control Studies. Codon. Female. Gene Expression. Glioblastoma / genetics. Glioblastoma / metabolism. Glioblastoma / mortality. Humans. Male. Middle Aged. Oncogene Protein p21(ras) / analysis. Oncogene Protein p21(ras) / metabolism. Polymorphism, Restriction Fragment Length. Reverse Transcriptase Polymerase Chain Reaction / methods. Statistics, Nonparametric. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19179066.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Codon; EC 3.6.5.2 / Oncogene Protein p21(ras)
  •  go-up   go-down


52. Hall WA, Doolittle ND, Daman M, Bruns PK, Muldoon L, Fortin D, Neuwelt EA: Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas. J Neurooncol; 2006 May;77(3):279-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two patients had biopsies that showed an astrocytoma and an anaplastic astrocytoma.
  • The median time to tumor progression was 15 months with the range from <1 to 40 months.
  • [MeSH-minor] Adolescent. Adult. Carboplatin / administration & dosage. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Male. Methotrexate / administration & dosage. Osmosis / drug effects. Retrospective Studies. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pharmacol Exp Ther. 1998 Jul;286(1):77-84 [9655844.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):1026-9; discussion 1029-30 [8133987.001]
  • [Cites] J Neurooncol. 1998 Nov;40(2):171-7 [9892099.001]
  • [Cites] Med Pediatr Oncol. 1998 Jan;30(1):28-33 [9371386.001]
  • [Cites] Cancer. 1996 Feb 1;77(3):555-62 [8630965.001]
  • [Cites] Neuro Oncol. 2003 Jan;5(1):8-13 [12626128.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Neurosurgery. 1995 Jul;37(1):17-27; discussion 27-8 [8587686.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1182-5 [12654425.001]
  • [Cites] Pediatr Neurosurg. 2001 Apr;34(4):206-14 [11359114.001]
  • [Cites] Pediatr Neurosurg. 1996;24(5):263-6 [8933570.001]
  • [Cites] Bull Cancer. 2004 Jun;91(6):E167-83 [15562562.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):685-92 [10649264.001]
  • [Cites] Childs Nerv Syst. 2004 Mar;20(3):143-53 [14669023.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):637-47 [10649259.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):959-64 [10192340.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):493-500 [11297239.001]
  • [Cites] Cancer. 1999 Sep 15;86(6):1064-9 [10491535.001]
  • (PMID = 16314949.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS33618; United States / NINDS NIH HHS / NS / NS34608; United States / NINDS NIH HHS / NS / NS44687
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


53. Ono A, Kanno H, Hayashi A, Nishimura S, Kyuma Y, Sato H, Ito S, Shimizu N, Chang CC, Gondo G, Yamamoto I, Sasaki T, Tanaka M: Collagen gel matrix assay as an in vitro chemosensitivity test for malignant astrocytic tumors. Int J Clin Oncol; 2007 Apr;12(2):125-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collagen gel matrix assay as an in vitro chemosensitivity test for malignant astrocytic tumors.
  • METHODS: We examined the chemosensitivites for four anticancer agents - 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3 (2-chloroethyl)-3-nitrosourea hydrochloride (ACNU), carboplatin, cisplatin, and etoposide - of 43 malignant astrocytic tumors (21 anaplastic astrocytomas and 22 glioblastomas) by using a collagen gel matrix assay, and we also determined the survival periods of the tumor-bearing patients.
  • RESULTS: For the anaplastic astrocytomas, the mean growth inhibitory rate was 33.2% with cisplatin, 37.2% with carboplatin, 28.0% with ACNU, and 24.8% with etoposide.
  • The median overall and progression-free survivals of anaplastic astrocytoma-bearing patients who had undergone chemotherapy with two anticancer drugs, both of which showed significant anticancer activity (growth inhibitory rate >30%) were significantly longer than those of the patients who had been treated with two drugs, one or both of which did not show significant anticancer activity.
  • Individual chemotherapy for malignant astrocytic tumors, based on chemosensitivity data, could contribute to longer survival, particularly in anaplastic astrocytoma-bearing patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / pathology. Carboplatin / therapeutic use. Cisplatin / therapeutic use. Collagen. Etoposide / therapeutic use. Nimustine / therapeutic use
  • [MeSH-minor] Adult. Aged. Central Nervous System Neoplasms / drug therapy. Disease Progression. Disease-Free Survival. Drug Screening Assays, Antitumor. Female. Fibrin Foam. Follow-Up Studies. Glioblastoma / drug therapy. Glioblastoma / pathology. Humans. Japan. Karnofsky Performance Status. Male. Middle Aged. Sensitivity and Specificity. Survival Analysis. Tissue Adhesives. Treatment Outcome. Tumor Burden / drug effects. Tumor Cells, Cultured / drug effects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1986 Apr;83(8):2694-8 [3458228.001]
  • [Cites] Prog Clin Biol Res. 1980;48:259-76 [7208520.001]
  • [Cites] J Neurooncol. 1983;1(2):149-66 [6088712.001]
  • [Cites] Int J Urol. 2005 Jan;12(1):67-72 [15661056.001]
  • [Cites] Lancet. 1982 Apr 17;1(8277):885-7 [6122104.001]
  • [Cites] Jpn J Cancer Res. 1991 May;82(5):607-12 [1648053.001]
  • [Cites] Eur J Cancer. 1996 Feb;32A(2):226-30 [8664032.001]
  • [Cites] Br J Cancer. 1983 Feb;47(2):205-14 [6297528.001]
  • [Cites] Urol Res. 1993 Mar;21(2):83-8 [8503152.001]
  • [Cites] Cancer Treat Rep. 1986 Dec;70(12):1379-82 [3791251.001]
  • [Cites] J Cancer Res Clin Oncol. 1999 Aug-Sep;125(8-9):481-6 [10480340.001]
  • [Cites] J Neurooncol. 1994;21(3):225-32 [7699417.001]
  • [Cites] Cancer Res. 1985 Sep;45(9):4200-5 [4028010.001]
  • [Cites] Cancer Res. 1982 Mar;42(3):992-8 [7199383.001]
  • (PMID = 17443280.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Fibrin Foam; 0 / Tissue Adhesives; 0S726V972K / Nimustine; 6PLQ3CP4P3 / Etoposide; 9007-34-5 / Collagen; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


54. Levin VA, Ictech S, Hess KR: Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas. BMC Cancer; 2007;7:106
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas.
  • BACKGROUND: To assess progression-free survival (PFS) as the appropriate end-point for phase II trials for anaplastic gliomas (AGs) and to determine the impact of PFS on survival-based phase III trials.
  • CONCLUSION: Based on PFS rates at 6, 9, and 12 months for AG patients, a differential of 1.5 to 2 years is the norm and could invalidate overall survival as an end-point for phase III studies in patients with AG.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / mortality. Brain Neoplasms / drug therapy. Brain Neoplasms / mortality. Oligodendroglioma / drug therapy. Oligodendroglioma / mortality
  • [MeSH-minor] Adult. Age Factors. Cluster Analysis. Disease-Free Survival. Humans. Kaplan-Meier Estimate. Karnofsky Performance Status. Least-Squares Analysis. Linear Models. Proportional Hazards Models. Recurrence. Reproducibility of Results. Research Design. Retrospective Studies. Severity of Illness Index. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2604-13 [10561328.001]
  • [Cites] Neurology. 1984 May;34(5):615-9 [6538653.001]
  • [Cites] Cancer Treat Rep. 1984 Jul-Aug;68(7-8):969-73 [6744348.001]
  • [Cites] Neurology. 1985 Feb;35(2):219-26 [3969210.001]
  • [Cites] J Neurooncol. 1985;3(1):19-21 [2987424.001]
  • [Cites] Cancer. 1985 Oct 1;56(7):1497-501 [4040799.001]
  • [Cites] J Neurosurg. 1986 Dec;65(6):799-806 [3021932.001]
  • [Cites] J Clin Oncol. 1987 Mar;5(3):464-71 [3029339.001]
  • [Cites] Am J Clin Oncol. 1988 Feb;11(1):52-4 [2829615.001]
  • [Cites] J Neurooncol. 1988 Dec;6(4):319-23 [3221259.001]
  • [Cites] J Neurooncol. 1989 May;7(1):5-11 [2754456.001]
  • [Cites] Cancer. 1989 Dec 15;64(12):2420-3 [2555038.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Neurooncol. 1991 Feb;10(1):27-30 [1902506.001]
  • [Cites] J Clin Oncol. 1991 Nov;9(11):1945-9 [1658242.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1432-7 [1380989.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Apr;16(4):715-26 [7611028.001]
  • [Cites] Cancer Res. 1996 May 1;56(9):1983-7 [8616836.001]
  • [Cites] J Neurooncol. 1997 Sep;34(2):145-51 [9210061.001]
  • [Cites] Neurology. 1998 Mar;50(3):777-81 [9521274.001]
  • [Cites] Clin Cancer Res. 1999 Feb;5(2):309-17 [10037179.001]
  • [Cites] J Neurooncol. 2006 Oct;80(1):83-90 [16639492.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Radiology. 2000 Nov;217(2):377-84 [11058631.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):509-18 [11208845.001]
  • [Cites] J Cell Biol. 2001 Mar 5;152(5):971-84 [11238453.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):981-90 [12631596.001]
  • [Cites] Cancer Res. 1970 Oct;30(10):2451-5 [5474173.001]
  • [Cites] Cancer Chemother Rep. 1974 Nov-Dec;58(6):787-92 [4447922.001]
  • [Cites] Cancer. 1975 Jun;35(6):1551-7 [1148989.001]
  • [Cites] Cancer Chemother Rep. 1975 Mar-Apr;59(2 Pt 1):327-31 [1149010.001]
  • [Cites] Adv Neurol. 1976;15:315-25 [779423.001]
  • [Cites] J Neurosurg. 1977 Feb;46(2):145-54 [833632.001]
  • [Cites] J Neurosurg. 1977 Sep;47(3):329-35 [894339.001]
  • [Cites] J Med Chem. 1980 Jun;23(6):682-4 [7392035.001]
  • [Cites] Cancer Treat Rep. 1980 Feb-Mar;64(2-3):237-44 [7407756.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2762-71 [10561351.001]
  • (PMID = 17587447.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC1919386
  •  go-up   go-down


55. Masoudi A, Elopre M, Amini E, Nagel ME, Ater JL, Gopalakrishnan V, Wolff JE: Influence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res; 2008 Jul-Aug;28(4C):2437-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of valproic acid on outcome of high-grade gliomas in children.
  • BACKGROUND: Chemotherapy has limited effects in the treatment of high-grade gliomas (HGGs).
  • MATERIALS AND METHODS: An analysis of 66 pediatric patients (range, 1-19 years of age) with glioblastoma multiforme (GBM) (n=40) or anaplastic astrocytoma (AA) (n=26) was retrospectively conducted for predictors of survival and response and for effects of VPA on outcome or toxicity.
  • [MeSH-major] Astrocytoma / drug therapy. Glioblastoma / drug therapy. Valproic Acid / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18751431.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 614OI1Z5WI / Valproic Acid
  •  go-up   go-down


56. Chamberlain MC, Johnston S: Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. J Neurooncol; 2009 Feb;91(3):359-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma.
  • A retrospective study of bevacizumab only in adults with recurrent temozolomide (TMZ)-refractory anaplastic astrocytoma (AA) with a primary objective of determining progression free survival (PFS).
  • Bevacizumab-related toxicity included fatigue (14 patients; 2 grade 3), leukopenia (7; 1 grade 3), deep vein thrombosis (5; 2 grade 3), hypertension (5; 1 grade 3), anemia (4; 0 grade 3) and wound dehiscence (1; 1 grade 3).
  • Time to tumor progression ranged from 1 to 20 months (median: 7).
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / mortality. Brain Neoplasms / drug therapy. Brain Neoplasms / mortality. Neoplasm Recurrence, Local
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Bevacizumab. Disease Progression. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1981 Nov;55(5):749-56 [7310496.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):860-4 [1849986.001]
  • [Cites] J Clin Oncol. 1992 Sep;10(9):1379-85 [1325539.001]
  • [Cites] Ann Neurol. 2003 Oct;54(4):479-87 [14520660.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):509-18 [11208845.001]
  • [Cites] Neuro Oncol. 2004 Jul;6(3):253-8 [15279718.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):640-6 [10931464.001]
  • [Cites] Eur J Cancer. 1997 Sep;33(10):1592-6 [9389920.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3389-95 [10550132.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):89-95 [17327573.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1063-71 [12569607.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] Stat Med. 1991 May;10(5):749-55 [2068428.001]
  • [Cites] Neurology. 2008 Mar 4;70(10):779-87 [18316689.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]
  • [Cites] Surg Neurol. 1993 Jun;39(6):538-43 [8390727.001]
  • [Cites] J Neurosurg. 2007 Apr;106(4):601-8 [17432710.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4 [2154418.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12 ):2305-11 [12805331.001]
  • [Cites] Neurology. 2006 Apr 25;66(8):1258-60 [16636248.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Clin Oncol. 1987 Mar;5(3):459-63 [3546620.001]
  • [Cites] Semin Oncol. 2000 Jun;27(3 Suppl 6):1-10 [10866344.001]
  • [Cites] J Neurosurg. 1990 Apr;72 (4):583-8 [2319317.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Aug;21(3):601-6 [1651302.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(1):3-8 [1572829.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(4):593-7 [1429080.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1213-20 [15022289.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1485-91 [12697871.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4714-21 [17947718.001]
  • (PMID = 18953491.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


57. Heimberger AB, McGary EC, Suki D, Ruiz M, Wang H, Fuller GN, Bar-Eli M: Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas. Clin Cancer Res; 2005 Jan 1;11(1):267-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas.
  • Anderson Cancer Center since 1986 to include 72 glioblastomas, 49 anaplastic astrocytomas, 9 low-grade astrocytoma, 37 oligodendrogliomas, 37 anaplastic oligodendrogliomas, 15 mixed oligoastrocytomas, 20 anaplastic mixed oligoastrocytomas, and 7 gliosarcomas.
  • RESULTS: AP-2alpha expression was lost on 99% (P < 0.001) and 98% (P < 0.001) of glioblastomas and anaplastic astrocytomas, respectively, compared with grade 2 astrocytomas and normal brain, all of which (100%) maintained expression of AP-2alpha.
  • However, there was no significant effect of loss of AP-2alpha expression on survival observed after adjustment for patient age, Karnofsky Performance Scale score, tumor grade, and extent of resection (rate ratio, 1.2; 95% confidence interval, 0.6-2.2; P = 0.6).
  • CONCLUSIONS: AP-2alpha expression correlates inversely with glioma grade, suggesting a direct role in glioma tumorigenicity, possibly through subsequent deregulation of target genes.
  • Of all the previously characterized markers of progression, the loss of AP-2alpha would be the most common (96.2%) molecular marker as an astrocytic tumor evolves from grade 2 to 3.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amino Acid Motifs. Antigens, CD / biosynthesis. Antigens, CD146. Astrocytoma / metabolism. Brain / metabolism. Cell Cycle Proteins / biosynthesis. Cell Line, Tumor. Child. Child, Preschool. Cyclin-Dependent Kinase Inhibitor p21. Disease Progression. Humans. Immunohistochemistry. Matrix Metalloproteinase 2 / biosynthesis. Middle Aged. Neural Cell Adhesion Molecules / biosynthesis. Oligodendroglioma / metabolism. Oligonucleotide Array Sequence Analysis. Prognosis. Proportional Hazards Models. Proto-Oncogene Proteins c-kit / biosynthesis. Time Factors. Transcription Factor AP-2. Treatment Outcome. Vascular Endothelial Growth Factor A / biosynthesis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671555.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / PHS HHS / / T-32-09666
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD146; 0 / CDKN1A protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / DNA-Binding Proteins; 0 / MCAM protein, human; 0 / Neural Cell Adhesion Molecules; 0 / TFAP2A protein, human; 0 / Transcription Factor AP-2; 0 / Transcription Factors; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


58. Ng WH, Lim T: Targeting regions with highest lipid content on MR spectroscopy may improve diagnostic yield in stereotactic biopsy. J Clin Neurosci; 2008 May;15(5):502-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomas are heterogeneous brain tumors and prognosis and treatment are dependent on the highest histological grade present.
  • MRS studies in brain tumors have found increased levels of choline-containing compounds (Cho) and decreased levels of N-acetylaspartate (NAA), creatine (Cr) and phosphocreatine (PCr) which are all associated with increased grade of glioma.
  • MRS was performed on two patients undergoing stereotactic biopsy for suspected astrocytoma.
  • Histological grade was found to be different in one case: the region with a high Lip/Cr and Cho/NAA ratios showed glioblastoma, whereas the region with high Cho/NAA but low Lip/Cr ratios showed anaplastic astrocytoma.
  • The second patient had high Cho/NAA ratio but low Lip/Cr ratio in both targets and the histology revealed anaplastic astrocytoma in both samples.
  • [MeSH-minor] Adult. Humans. Male. Middle Aged. Stereotaxic Techniques

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18334298.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Lipids
  •  go-up   go-down


59. Brada M, Ashley S, Dowe A, Gonsalves A, Huchet A, Pesce G, Reni M, Saran F, Wharram B, Wilkins M, Wilkins P: Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide. Ann Oncol; 2005 Jun;16(6):942-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: This was a multicentre phase II study of chemotherapy in patients with histologically verified glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA) who had undergone biopsy alone.

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15870090.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


60. Silvani A, Gaviani P, Fiumani A, Scaioli V, Lamperti E, Eoli M, Botturi A, Salmaggi A: Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas. J Neurooncol; 2009 Oct;95(1):61-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PFS-6 was achieved in five patients (33%), three with glioblastoma multiforme and two with anaplastic astrocytoma.
  • [MeSH-minor] Adolescent. Adult. Aged. Drug Administration Schedule. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Severity of Illness Index. Survival Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuro Oncol. 2009 Apr;11(2):158-66 [18780814.001]
  • [Cites] Neurology. 2006 Feb 28;66(4):587-9 [16505319.001]
  • [Cites] Cancer J. 2008 Sep-Oct;14 (5):279-85 [18836331.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2069-80 [10561260.001]
  • [Cites] Angew Chem Int Ed Engl. 2006 Dec 4;45(47):7942-8 [17006870.001]
  • [Cites] Expert Opin Investig Drugs. 2008 Nov;17(11):1735-48 [18922109.001]
  • [Cites] Oncologist. 2006 Feb;11(2):165-80 [16476837.001]
  • [Cites] Clin Neurol Neurosurg. 1997 May;99(2):117-23 [9213056.001]
  • [Cites] Cancer Res. 2008 Jul 1;68(13):5301-8 [18593931.001]
  • [Cites] J Neurooncol. 2003 Nov;65(2):99-106 [14686728.001]
  • [Cites] Drugs. 2008;68(2):139-46 [18197722.001]
  • [Cites] Anticancer Drugs. 2008 Jul;19(6):613-20 [18525321.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • (PMID = 19381446.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzothiazoles; 0 / Epothilones; 0 / sagopilone
  •  go-up   go-down


61. Antonelli M, Buttarelli FR, Arcella A, Nobusawa S, Donofrio V, Oghaki H, Giangaspero F: Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas. J Neurooncol; 2010 Sep;99(2):209-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas.
  • The objective of this study was to evaluate, in a series of 43 pediatric high-grade gliomas (21 anaplastic astrocytoma WHO grade III and 22 glioblastoma WHO grade IV), the prognostic value of histological grading and expression of p53 and YKL-40.
  • The prognostic stratification for histological grading showed no difference in overall (OS) and progression-free survival (PFS) between glioblastomas and anaplastic astrocytomas.
  • TP53 mutations were detected in five of 27 (18%) cases (four glioblastomas and one anaplastic astrocytoma).
  • Our results suggest that in pediatric high-grade gliomas: (i) histological grading does not have strong prognostic significance, (ii) YKL-40 overexpression is less frequent than adult high-grade gliomas and does not correlate with a more aggressive behavior, (iii) TP53 mutations but not p53 expression may correlate with a more aggressive behavior, and (iv) IDH1 mutations are absent.
  • These observations support the concept that, despite identical histological features, the biology of high-grade gliomas in children differs from that in adults, and therefore different prognostic factors are needed.
  • [MeSH-major] Astrocytoma / genetics. Astrocytoma / metabolism. Glycoproteins / metabolism. Isocitrate Dehydrogenase / genetics. Lectins / metabolism. Mutation / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adipokines. Adolescent. Adult. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Child. Child, Preschool. Chitinase-3-Like Protein 1. DNA, Neoplasm / genetics. Female. Humans. Immunoenzyme Techniques. Infant. Infant, Newborn. Male. Neoplasm Staging. Polymerase Chain Reaction. Prognosis. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Oncol Rep. 2009 Jan;11(1):68-72 [19080744.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] J Neurooncol. 2005 Dec;75(3):267-72 [16195804.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3155-64 [11753995.001]
  • [Cites] Neuro Oncol. 2009 Aug;11(4):341-7 [19435942.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7):888-93 [17554787.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] J Clin Oncol. 2009 Sep 1;27(25):4150-4 [19636000.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Biochem J. 2002 Jul 1;365(Pt 1):119-26 [12071845.001]
  • [Cites] Hum Pathol. 1999 Nov;30(11):1284-90 [10571506.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Acta Neuropathol. 2008 Dec;116(6):597-602 [18985363.001]
  • [Cites] N Engl J Med. 2009 May 21;360(21):2248; author reply 2249 [19458374.001]
  • [Cites] Neuro Oncol. 2009 Jun;11(3):274-80 [18981259.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3326-34 [15867231.001]
  • [Cites] Acta Neuropathol. 2004 Jul;108(1):49-56 [15118874.001]
  • [Cites] J Neurosurg. 1991 Jan;74(1):27-37 [1984503.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12 (13):3935-41 [16818690.001]
  • [Cites] Clin Cancer Res. 2009 Oct 1;15(19):6002-7 [19755387.001]
  • [Cites] Curr Probl Cancer. 2008 May-Jun;32(3):97-123 [18501774.001]
  • [Cites] Recent Results Cancer Res. 2009;171:67-81 [19322538.001]
  • [Cites] N Engl J Med. 2009 Feb 19;360(8):765-73 [19228619.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1525-32 [11290570.001]
  • [Cites] J Clin Oncol. 2007 Apr 1;25(10):1196-208 [17401009.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7404-7 [11606370.001]
  • [Cites] J Neurosurg. 1997 Jan;86(1):121-30 [8988090.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):264-71 [11815986.001]
  • [Cites] Neurosurgery. 1995 Aug;37(2):246-54 [7477776.001]
  • [Cites] Exp Cell Res. 1999 Jul 10;250(1):168-73 [10388530.001]
  • [Cites] N Engl J Med. 2002 Feb 7;346(6):420-7 [11832530.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6284-92 [17975139.001]
  • (PMID = 20174854.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adipokines; 0 / CHI3L1 protein, human; 0 / Chitinase-3-Like Protein 1; 0 / DNA, Neoplasm; 0 / Glycoproteins; 0 / Lectins; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.42. / IDH1 protein, human
  •  go-up   go-down


62. Dong L, Pu PY, Wang H, Wang GX, Kang CS, Jiao DR: [Study on the expression of epidermal growth factor receptor and p53 in astrocytic gliomas: evidence for a distinct genetic pathway]. Zhonghua Bing Li Xue Za Zhi; 2006 Apr;35(4):232-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study on the expression of epidermal growth factor receptor and p53 in astrocytic gliomas: evidence for a distinct genetic pathway].
  • OBJECTIVE: To study further the most important and frequent genetic alterations of p53 and epidermal growth factor receptor (EGFR) in astrocytic gliomas. METHODS:.
  • (1) EGFR expression was examined in samples collected from 37 astrocytic gliomas and 6 normal brain tissue using reverse transcriptase polymerase chain reaction and immunohistochemical staining. (2) p53 gene mutation and accumulation were detected simultaneously in the same specimens using PCR-SSCP, DNA sequencing and immunohistochemical staining.
  • RESULTS: The frequency of p53 mutation in diffuse astrocytomas, anaplastic astrocytomas, primary glioblastomas and secondary glioblastomas was 1/10, 4/19 (21.1%), 4/6 and 2/2, respectively and the frequency of EGFR overexpression was 5/10, 10/19 (52.6%), 5/6 and 2/2, respectively.
  • CONCLUSIONS: EGFR overexpression is not infrequently seen, however, p53 mutation is rarely seen in the low grade gliomas.
  • Consequently, EGFR overexpression and p53 gene mutation are not mutually exclusive in astrocytic gliomagenesis but synergistically to promote the glioma progression.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Receptor, Epidermal Growth Factor / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Aged. Base Sequence. DNA Mutational Analysis. Female. Gene Expression Regulation, Neoplastic. Glioblastoma / genetics. Glioblastoma / metabolism. Glioblastoma / pathology. Humans. Immunohistochemistry. Male. Middle Aged. Molecular Sequence Data. Mutation. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16776982.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


63. Kim B, Chung CK, Myung JK, Park SH: Pleomorphic xanthoastrocytoma associated with long-standing Taylor-type IIB-focal cortical dysplasia in an adult. Pathol Res Pract; 2009;205(2):113-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic xanthoastrocytoma associated with long-standing Taylor-type IIB-focal cortical dysplasia in an adult.
  • Brain tumor in combination with cortical dysplasia is one of the causes of epilepsy, but coexistence of these two entities is a rare event.
  • Later, he was admitted as an emergency case because of severe headache, and the tumor was removed.
  • The tumor was diagnosed as PXA with anaplastic feature (mitotic count: 5/10HPF), and the brain around the tumor showed dysmorphic neurons and balloon cells.
  • Therefore, the tumor was assumed to be associated with the brain, with Taylor-type-IIB focal cortical dysplasia.
  • The patient's condition deteriorated, with tumor recurrence and widespread leptomeningeal seeding to the whole spinal cord.
  • He died 17 months after tumor removal.
  • [MeSH-major] Astrocytoma / complications. Astrocytoma / pathology. Brain Neoplasms / complications. Brain Neoplasms / pathology. Epilepsy, Temporal Lobe / complications. Malformations of Cortical Development / complications

  • Genetic Alliance. consumer health - Pleomorphic xanthoastrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18657915.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


64. Shrivastava RK, Epstein FJ, Perin NI, Post KD, Jallo GI: Intramedullary spinal cord tumors in patients older than 50 years of age: management and outcome analysis. J Neurosurg Spine; 2005 Mar;2(3):249-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Intramedullary spinal cord tumors (IMSCTs) in the older-age adult population pose complex management issues regarding the extent of resection and functional outcome, especially in terms of quality of life.
  • Historically, IMSCTs in the older adult population were treated with irradiation alone because it was assumed that functional recovery would be poor.
  • Ependymoma was the most common tumor (83%), and 55% were located in the thoracic spine.
  • There were two deaths due tumor progression (both malignant tumors) and one recurrence (anaplastic astrocytoma).
  • The longer prodromal period in the older adult population may reflect the fact that their diagnosis and workup is inadequate.
  • The authors recommend motor evoked potential-guided aggressive microsurgical resection, because the long-term outcome of benign lesions is excellent (good functional recovery and no tumor recurrence).
  • [MeSH-minor] Aged. Astrocytoma / surgery. Chi-Square Distribution. Female. Humans. Male. Middle Aged. Quality of Life. Retrospective Studies. Survival Rate. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15796348.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Mandonnet E, Pallud J, Fontaine D, Taillandier L, Bauchet L, Peruzzi P, Guyotat J, Bernier V, Baron MH, Duffau H, Capelle L: Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection. Neurosurg Rev; 2010 Jan;33(1):91-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection.
  • Grade II gliomas grow slowly and linearly (at rates about 4 mm/year) before undergoing anaplastic transformation.
  • In order to analyze how surgery may affect radiological grade II glioma kinetics, we restrospectively reviewed our national database searching for patients operated on for a supratentorial grade II glioma between 1997 and 2007.
  • Statistical analysis showed no difference between this distribution and the distribution of preoperative growth rates in a previous series of 143 grade II gliomas.
  • In summary, inter- and intrapatient comparison of pre- and postoperative growth rates proves that surgery does not change grade II glioma dynamics, thus, acting as a cytoreduction.
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / pathology. Astrocytoma / surgery. Child. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Databases, Factual. Disease Progression. Female. Follow-Up Studies. Humans. Kinetics. Linear Models. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Oligodendroglioma / pathology. Oligodendroglioma / surgery. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2008 Oct;63(4):700-7; author reply 707-8 [18981880.001]
  • [Cites] Ann Neurol. 2007 May;61(5):484-90 [17469128.001]
  • [Cites] J Neurosurg. 2005 Sep;103(3):428-38 [16235673.001]
  • [Cites] Brain. 2005 Mar;128(Pt 3):678-87 [15689365.001]
  • [Cites] Eur J Radiol. 2009 Oct;72(1):54-64 [18632238.001]
  • [Cites] J Neurosurg. 2006 Feb;104(2):238-53 [16509498.001]
  • [Cites] Neuro Oncol. 2009 Apr;11(2):176-82 [18697954.001]
  • [Cites] Neurosurg Rev. 2008 Jul;31(3):263-9 [18299912.001]
  • [Cites] Cancer Res. 1994 Aug 15;54(16):4334-41 [7519120.001]
  • [Cites] J Clin Oncol. 2008 Mar 10;26(8):1338-45 [18323558.001]
  • [Cites] Neuroradiology. 2001 Feb;43(2):129-33 [11326557.001]
  • [Cites] Ann Neurol. 2003 Apr;53(4):524-8 [12666121.001]
  • [Cites] Arch Surg. 1998 Apr;133(4):383-9 [9565118.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98 [14625221.001]
  • [Cites] Ann Neurol. 2006 Sep;60(3):380-3 [16983683.001]
  • [Cites] Neurosurgery. 2008 Apr;62(4):753-64; discussion 264-6 [18496181.001]
  • (PMID = 19847462.001).
  • [ISSN] 1437-2320
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  •  go-up   go-down


66. Comincini S, Paolillo M, Barbieri G, Palumbo S, Sbalchiero E, Azzalin A, Russo MA, Schinelli S: Gene expression analysis of an EGFR indirectly related pathway identified PTEN and MMP9 as reliable diagnostic markers for human glial tumor specimens. J Biomed Biotechnol; 2009;2009:924565
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression analysis of an EGFR indirectly related pathway identified PTEN and MMP9 as reliable diagnostic markers for human glial tumor specimens.
  • To verify if this correlation was conserved in gliomas, PTEN and MMP9 expression was further investigated in an additional panel of 16 anaplastic astrocytoma specimens and, in parallel, in different human normal and astrocytic tumor cell lines.
  • In anaplastic astrocytomas PTEN expression was significantly higher than in glioblastoma multiforme, but no significant correlation was found between PTEN and MMP9 expression.
  • In conclusion, this gene expression survey highlighted that the combined measurement of PTEN and MMP9 transcripts might represent a novel reliable tool for the differential diagnosis of high-grade gliomas, and it also suggested a functional link involving these genes in glial tumors.
  • [MeSH-major] Biomarkers, Tumor / genetics. Gene Expression Regulation, Neoplastic. Glioma / diagnosis. Glioma / enzymology. Matrix Metalloproteinase 9 / metabolism. PTEN Phosphohydrolase / metabolism. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gene Expression Profiling. Humans. Male. Middle Aged. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Young Adult

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genome Biol. 2001;2(1):RESEARCH0003 [11178280.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3286-94 [18451155.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6885-91 [11559565.001]
  • [Cites] Brain Pathol. 2002 Jan;12(1):108-16 [11771519.001]
  • [Cites] Neuro Oncol. 2002 Jul;4(3):196-211 [12084351.001]
  • [Cites] Anal Biochem. 2002 Oct 15;309(2):293-300 [12413463.001]
  • [Cites] Biotechniques. 2004 Jan;36(1):84-6, 88, 90-1 [14740490.001]
  • [Cites] Science. 2004 Feb 20;303(5661):1179-81 [14976311.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):1943-50 [15026328.001]
  • [Cites] Curr Opin Oncol. 1999 May;11(3):162-7 [10328589.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):137-60 [15674475.001]
  • [Cites] Brain Tumor Pathol. 2004;21(3):105-12 [15696970.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):686-91 [15705860.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5814-9 [15827123.001]
  • [Cites] Biochim Biophys Acta. 2005 Aug 1;1751(1):110-7 [16054021.001]
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):867-74 [16424019.001]
  • [Cites] Cancer Sci. 2006 May;97(5):341-7 [16630129.001]
  • [Cites] Int J Oncol. 2006 Jul;29(1):73-81 [16773187.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 May;65(5):516-27 [16772875.001]
  • [Cites] J Neurooncol. 2006 Aug;79(1):1-7 [16557350.001]
  • [Cites] Curr Med Chem. 2006;13(29):3483-92 [17168718.001]
  • [Cites] Oncogene. 2007 Mar 29;26(14):2006-16 [17001310.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):13-24 [17520692.001]
  • [Cites] BMC Genomics. 2007;8:243 [17640361.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):7960-5 [17804702.001]
  • [Cites] Annu Rev Pathol. 2006;1:97-117 [18039109.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):779-86 [11549567.001]
  • (PMID = 19657395.001).
  • [ISSN] 1110-7251
  • [Journal-full-title] Journal of biomedicine & biotechnology
  • [ISO-abbreviation] J. Biomed. Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / RNA, Messenger; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ PMC2718324
  •  go-up   go-down


67. Maciá Escalante S, Rodríguez Lescure A, Segura Ibáñez JM, Sáez Castán J, Guillén Ponce C, Carrato Mena A: Patient with resected anaplastic astrocytoma and an image suggestive of relapse. Clin Transl Oncol; 2006 Dec;8(12):912-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient with resected anaplastic astrocytoma and an image suggestive of relapse.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Edema / diagnostic imaging. Brain Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Carmustine / administration & dosage. Carmustine / adverse effects. Combined Modality Therapy. Decanoic Acids / administration & dosage. Decanoic Acids / adverse effects. Female. Humans. Magnetic Resonance Imaging. Neurosurgical Procedures. Polyesters / administration & dosage. Polyesters / adverse effects. Positron-Emission Tomography. Radiography. Radiotherapy

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Invest New Drugs. 2004 Jan;22(1):27-37 [14707492.001]
  • [Cites] Neuro Oncol. 2005 Jan;7(1):84-9 [15701285.001]
  • [Cites] N Engl J Med. 2005 Jun 2;352(22):2350-3; author reply 2350-3 [15938011.001]
  • [Cites] Expert Opin Investig Drugs. 2005 Jun;14(6):643-58 [16004593.001]
  • (PMID = 17169765.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Decanoic Acids; 0 / Polyesters; 90409-78-2 / decanedioic acid-4,4'-(1,3-propanediylbis(oxy))bis(benzoic acid) copolymer; U68WG3173Y / Carmustine
  •  go-up   go-down


68. Hiremath GK, Bingaman WE, Prayson RA, Nair D: Oligoastrocytoma presenting with intractable epilepsy. Epileptic Disord; 2007 Sep;9(3):315-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Oligoastrocytomas (OA) are mixed gliomas with distinct oligodendroglial and astrocytic neoplastic components.
  • Surgical pathology revealed low-grade OA (WHO II) in five patients, and anaplastic OA in one.
  • There were no surgical complications, clinical or radiographic tumor recurrence at a mean follow up period of 3.2 years (range 2-8).
  • CONCLUSION: As a result of our small sample size, general conclusions may be imprecise, but this review suggests that OA behave similar to other tumors related to intractable epilepsy: they usually have a preoperative seizure course of many years, an excellent rate of seizure-freedom following surgery, and are in general, low-grade tumors with an indolent course for which serial imaging is sufficient follow-up.
  • [MeSH-major] Astrocytoma / complications. Brain Neoplasms / complications. Epilepsy / drug therapy. Epilepsy / etiology
  • [MeSH-minor] Adolescent. Adult. Anticonvulsants / therapeutic use. Craniotomy. Drug Resistance. Epilepsy, Complex Partial / etiology. Epilepsy, Complex Partial / surgery. Female. Humans. Magnetic Resonance Imaging. Male. Memory / physiology. Neoplasm Recurrence, Local. Neurosurgical Procedures. Temporal Lobe / pathology. Temporal Lobe / surgery

  • Genetic Alliance. consumer health - Epilepsy.
  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17884756.001).
  • [ISSN] 1294-9361
  • [Journal-full-title] Epileptic disorders : international epilepsy journal with videotape
  • [ISO-abbreviation] Epileptic Disord
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down


69. Mennel HD, Lell B: Ganglioside (GD2) expression and intermediary filaments in astrocytic tumors. Clin Neuropathol; 2005 Jan-Feb;24(1):13-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ganglioside (GD2) expression and intermediary filaments in astrocytic tumors.
  • The search of proliferation markers in astrocytic tumors that may serve as targets for therapeutic interventions, is in full progress.
  • Gangliosides are lipid-sugar compounds localized on the cell membrane that are thought to modify pertinent signals and, therefore, may influence a variety of functions in normal and pathologic conditions including those that act upon tumor growth.
  • Intracranial supratentorial astrocytic gliomas of the adult represent a tumor group, that may be divided into three grades of malignancy, the most anaplastic member being the glioblastoma.
  • Yet, the results were only partly congruent and the correlation to tumor grades rather loose.
  • Thus, the conclusion must be drawn that the correlation of ganglioside patterns to the proliferation of astrocytic tumors is as poor as that of GFAP or vimentin expression, respectively.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Gangliosides / metabolism. Intermediate Filaments / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15696779.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Gangliosides; 0 / Glial Fibrillary Acidic Protein; 0 / Vimentin; 65988-71-8 / ganglioside, GD2
  •  go-up   go-down


70. Gupta B, Raina J: Fascicular multiple ocular motor nerve paresis as first presentation of anaplastic astrocytoma. Indian J Ophthalmol; 2007 Nov-Dec;55(6):458-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fascicular multiple ocular motor nerve paresis as first presentation of anaplastic astrocytoma.
  • A case of spontaneous, painless partial III (pupil-sparing) and IV fascicular nerve paresis as the first presentation of anaplastic astrocytoma is reported.
  • [MeSH-major] Astrocytoma / complications. Brain Stem Neoplasms / complications. Oculomotor Nerve Diseases / etiology
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Eye Movements. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiologe. 1999 Oct;39(10):821-7 [10550380.001]
  • [Cites] Acta Neurochir (Wien). 1979;49(1-2):35-45 [230705.001]
  • [Cites] J Clin Neurosci. 2005 Nov;12(8):946-9 [16326274.001]
  • [Cites] Neurol Neurochir Pol. 1983 Jul-Aug;17(4):471-5 [6646330.001]
  • [Cites] Neurosurgery. 1982 Apr;10(4):437-44 [7099393.001]
  • (PMID = 17951905.001).
  • [ISSN] 0301-4738
  • [Journal-full-title] Indian journal of ophthalmology
  • [ISO-abbreviation] Indian J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2635986
  •  go-up   go-down


71. Liu L, Bäcklund LM, Nilsson BR, Grandér D, Ichimura K, Goike HM, Collins VP: Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. J Mol Med (Berl); 2005 Nov;83(11):917-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas.
  • The aim of this study was to evaluate the clinical value of assessing epidermal growth factor receptor (EGFR) amplification and the common 5' rearrangement of EGFR resulting in the EGFRvIII transcript in astrocytic gliomas.
  • Amplification of EGFR was found in 41% (65/160) of glioblastomas (GBs) and 10% (4/41) of anaplastic astrocytomas (AAs).
  • There were no abnormalities of the EFGR or its transcript in grade II astrocytoma (AII).
  • [MeSH-major] Astrocytoma / genetics. Central Nervous System Neoplasms / genetics. Gene Amplification. Glioblastoma / genetics. Glioma / genetics. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adult. Age Factors. Biomarkers / analysis. Female. Gene Dosage. Humans. Male. Middle Aged. Mutation. Polymerase Chain Reaction / methods. Survival Analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):639-44 [12515857.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18 Suppl):41S-44S [11560970.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6962-70 [14583498.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):972-5 [14967458.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Jul;63(7):700-7 [15290895.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Biometrika. 1965 Dec;52(3):650-3 [5858975.001]
  • [Cites] Cancer Res. 1984 Mar;44(3):1002-7 [6318979.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jun;87(11):4207-11 [1693434.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Nov;87(21):8602-6 [2236070.001]
  • [Cites] Cancer Res. 1991 Apr 15;51(8):2164-72 [2009534.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(1):225-30 [1309204.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2965-9 [1557402.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 15;89(10):4309-13 [1584765.001]
  • [Cites] Cancer Res. 1994 Feb 15;54(4):1008-15 [8313355.001]
  • [Cites] Cancer Res. 1994 Jun 15;54(12):3127-30 [8205529.001]
  • [Cites] Oncogene. 1994 Aug;9(8):2313-20 [8036013.001]
  • [Cites] Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232 [7612182.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23):5536-9 [7585629.001]
  • [Cites] Cancer Res. 1996 Sep 1;56(17):3859-61 [8752145.001]
  • [Cites] Oncogene. 1996 Sep 5;13(5):1065-72 [8806696.001]
  • [Cites] Clin Cancer Res. 1998 Jan;4(1):215-22 [9516974.001]
  • [Cites] Oncol Res. 1997;9(11-12):581-7 [9563005.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Jul;57(7):684-9 [9690672.001]
  • [Cites] Int J Oncol. 1998 Oct;13(4):717-24 [9735401.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Dec;57(12):1138-45 [9862636.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1383-7 [10728703.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7503-8 [10852962.001]
  • [Cites] Cell. 2000 Oct 13;103(2):211-25 [11057895.001]
  • [Cites] Oncol Res. 2000;12(2):107-12 [11132923.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56 [11504770.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4151-8 [14519639.001]
  • (PMID = 16133418.001).
  • [ISSN] 0946-2716
  • [Journal-full-title] Journal of molecular medicine (Berlin, Germany)
  • [ISO-abbreviation] J. Mol. Med.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A6618
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / epidermal growth factor receptor VIII; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2815848; NLM/ UKMS2690
  •  go-up   go-down


72. Parsa CF, Givrad S: Juvenile pilocytic astrocytomas do not undergo spontaneous malignant transformation: grounds for designation as hamartomas. Br J Ophthalmol; 2008 Jan;92(1):40-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To determine whether juvenile pilocytic astrocytomas WHO grade I have the potential for spontaneous malignant transformation.
  • METHODS: A literature search was performed, cross-referencing juvenile pilocytic astrocytoma, pilocytic astrocytoma, astrocytoma grade I, optic glioma, glioma, low-grade gliomas, polar spongioblastoma, gliocytoma embryonale, and malignant transformation, anaplasia or anaplastic change.
  • Twenty-two of these tumours, however, did not initially match criteria for juvenile pilocytic astrocytoma WHO grade I and were excluded.
  • CONCLUSION: Juvenile pilocytic astrocytomas WHO grade I do not undergo spontaneous anaplastic transformation.
  • [MeSH-major] Astrocytoma / pathology. Brain Diseases / pathology. Brain Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Hamartoma / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease Progression. Humans. Middle Aged. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology


73. Kirby S, Gertler SZ, Mason W, Watling C, Forsyth P, Aniagolu J, Stagg R, Wright M, Powers J, Eisenhauer EA: Phase 2 study of T138067-sodium in patients with malignant glioma: Trial of the National Cancer Institute of Canada Clinical Trials Group. Neuro Oncol; 2005 Apr;7(2):183-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with recurrent anaplastic astrocytoma or glioblastoma multiforme were treated intravenously with 330 mg/m(2) of T138067-sodium weekly.
  • There were two patients with anaplastic astrocytoma and 16 with glioblastoma multiforme.
  • Our results suggest that given in this dose and schedule T138067-sodium does not have activity in this population of anaplastic astrocytoma and glioblastoma multiforme.
  • [MeSH-minor] Adult. Aged. Canada. Female. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Arch Pathol Lab Med. 2001 May;125(5):613-24 [11300931.001]
  • [Cites] J Med Chem. 2001 Oct 25;44(22):3599-605 [11606124.001]
  • [Cites] Cochrane Database Syst Rev. 2002;(4):CD003913 [12519620.001]
  • [Cites] Cell Motil Cytoskeleton. 2003 Sep;56(1):45-56 [12905530.001]
  • [Cites] Biochim Biophys Acta. 2001;1471(2):O1-9 [11342188.001]
  • [Cites] Biometrics. 1982 Mar;38(1):143-51 [7082756.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5686-91 [10318945.001]
  • [Cites] J Neurosurg. 1977 Sep;47(3):329-35 [894339.001]
  • (PMID = 15831236.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Sulfonamides; T4NP8G3K6Q / batabulin
  • [Other-IDs] NLM/ PMC1871890
  •  go-up   go-down


74. Seo HS, Kim JH, Lee DH, Lee YH, Suh SI, Kim SY, Na DG: Nonenhancing intramedullary astrocytomas and other MR imaging features: a retrospective study and systematic review. AJNR Am J Neuroradiol; 2010 Mar;31(3):498-503
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: Most intramedullary astrocytomas have been known to exhibit at least some enhancement on MR imaging regardless of cell type or tumor grade.
  • MATERIALS AND METHODS: A total of 19 consecutive patients (male to female ratio, 11:8; mean age, 27.84 +/- 19.0 years) with primary intramedullary astrocytomas (3 WHO grade I, 13 WHO grade II, 3 WHO grade III) who underwent preoperative MR imaging with contrast enhancement were included in this retrospective study from 4 institutions.
  • The tumor-enhancement patterns were classified into the following categories:.
  • RESULTS: In the retrospective study, 6 astrocytomas (32%), including 2 anaplastic astrocytomas, did not enhance at all.
  • In the literature review, the frequency of nonenhancing intramedullary astrocytomas was 14 of 76 (18%), including 2 anaplastic astrocytomas.
  • Therefore, astrocytoma must remain in the differential diagnosis of nonenhancing intramedullary lesions, particularly if the lesion demonstrates a prominent mass effect or cord expansion.
  • [MeSH-major] Astrocytoma / pathology. Magnetic Resonance Imaging / methods. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Contrast Media. Diagnosis, Differential. Female. Gadolinium DTPA. Humans. Male. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19875469.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  • [Number-of-references] 21
  •  go-up   go-down


75. Massimino M, Gandola L, Luksch R, Spreafico F, Riva D, Solero C, Giangaspero F, Locatelli F, Podda M, Bozzi F, Pignoli E, Collini P, Cefalo G, Zecca M, Casanova M, Ferrari A, Terenziani M, Meazza C, Polastri D, Scaramuzza D, Ravagnani F, Fossati-Bellani F: Sequential chemotherapy, high-dose thiotepa, circulating progenitor cell rescue, and radiotherapy for childhood high-grade glioma. Neuro Oncol; 2005 Jan;7(1):41-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential chemotherapy, high-dose thiotepa, circulating progenitor cell rescue, and radiotherapy for childhood high-grade glioma.
  • Histologies were glioblastoma multiforme in 10, anaplastic astrocytoma in nine, and anaplastic oligodendroglioma in two; sites of origin were supratentorial areas in 17, spine in two, and posterior fossa in two.
  • Four of 12 relapsed children had tumor dissemination.
  • [MeSH-minor] Adolescent. Adult. Blood Component Transfusion. Child. Child, Preschool. Combined Modality Therapy. Erythroid Precursor Cells. Female. Humans. Male. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. THIO-TEPA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 1996 Dec;18 Suppl 3:S1-5 [8971398.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2495-503 [8823328.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;40(1):72-4 [9137533.001]
  • [Cites] Anticancer Res. 1997 May-Jun;17(3C):2073-7 [9216666.001]
  • [Cites] Ann Genet. 1997;40(2):78-91 [9259954.001]
  • [Cites] Med Pediatr Oncol. 1997 Dec;29(6):553-9 [9324343.001]
  • [Cites] Med Pediatr Oncol. 1998 Feb;30(2):75-80 [9403013.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):210-21 [9440745.001]
  • [Cites] Childs Nerv Syst. 1997 Nov-Dec;13(11-12):572-7 [9454971.001]
  • [Cites] J Natl Cancer Inst. 1998 Apr 15;90(8):606-11 [9554443.001]
  • [Cites] J Neurosurg. 1998 Jul;89(1):52-9 [9647172.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2486-93 [9667268.001]
  • [Cites] Klin Padiatr. 1998 Jul-Aug;210(4):227-33 [9743957.001]
  • [Cites] Bone Marrow Transplant. 1998 Oct;22(7):661-7 [9818693.001]
  • [Cites] Med Pediatr Oncol. 1998 Dec;31(6):483-90 [9835900.001]
  • [Cites] Med Pediatr Oncol. 1999 Aug;33(2):83-7 [10398181.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):2117-23 [10570440.001]
  • [Cites] Childs Nerv Syst. 1999 Nov;15(11-12):786-8 [10603023.001]
  • [Cites] Med Pediatr Oncol. 2000 Feb;34(2):147-50 [10657880.001]
  • [Cites] Childs Nerv Syst. 2000 Jan;16(1):15-20 [10672424.001]
  • [Cites] Bone Marrow Transplant. 2000 Jul;26(2):153-60 [10918425.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):264-71 [11815986.001]
  • [Cites] N Engl J Med. 2002 Feb 7;346(6):420-7 [11832530.001]
  • [Cites] Eur J Cancer. 2002 Apr;38(6):815-9 [11937316.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3569-72 [12552957.001]
  • [Cites] Neurosurgery. 1987 Mar;20(3):416-20 [3574617.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1221-31 [3040919.001]
  • [Cites] Cancer Res. 1989 Feb 1;49(3):736-41 [2491958.001]
  • [Cites] J Neurooncol. 1989 May;7(1):5-11 [2754456.001]
  • [Cites] J Neurooncol. 1989 Jul;7(2):165-77 [2550594.001]
  • [Cites] J Neurosurg. 1990 Apr;72(4):583-8 [2319317.001]
  • [Cites] Cancer. 1990 Jun 15;65(12):2771-8 [2160318.001]
  • [Cites] Bone Marrow Transplant. 1992 Apr;9(4):227-33 [1534708.001]
  • [Cites] Int J Cancer. 1993 Apr 22;54(1):112-8 [8478137.001]
  • [Cites] N Engl J Med. 1993 Jun 17;328(24):1725-31 [8388548.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1458-65 [8336185.001]
  • [Cites] Med Pediatr Oncol. 1994;23(5):428-36 [8084310.001]
  • [Cites] Med Pediatr Oncol. 1995 Feb;24(2):104-8 [7990757.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):112-23 [7799011.001]
  • [Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]
  • [Cites] Eur J Cancer. 1997 Jan;33(1):91-5 [9071906.001]
  • (PMID = 15701281.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 905Z5W3GKH / Thiotepa
  • [Other-IDs] NLM/ PMC1871624
  •  go-up   go-down


76. Kohshi K, Yamamoto H, Nakahara A, Katoh T, Takagi M: Fractionated stereotactic radiotherapy using gamma unit after hyperbaric oxygenation on recurrent high-grade gliomas. J Neurooncol; 2007 May;82(3):297-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fractionated stereotactic radiotherapy using gamma unit after hyperbaric oxygenation on recurrent high-grade gliomas.
  • BACKGROUND: To reduce this complication and to enhance the radiation effect to hypoxic cells of high-grade gliomas, the authors performed noninvasive fractionated stereotactic radiotherapy (FSRT) using a Gamma unit combined with hyperbaric oxygen (HBO) therapy for the treatment of recurrent disease.
  • PATIENTS AND METHODS: Twenty-five consecutive patients who had previously received radiotherapy with chemotherapy for recurrent high-grade gliomas, including 14 patients with anaplastic astrocytoma (AA) and 11 with glioblastoma multiforme (GBM), underwent Gamma FSRT immediately after HBO therapy (2.5 atmospheres absolute for 60 min).
  • Median tumor volume was 8.7 cc (range, 1.7-159.3 cc), and the median total radiation dose was 22 Gy (range, 18-27 Gy) to the tumor margin in 8 fractions.
  • CONCLUSION: Gamma FSRT after HBO therapy appears to confer a survival benefit for patients with recurrent high-grade gliomas and warrants further investigation.
  • [MeSH-major] Brain Neoplasms / therapy. Glioma / therapy. Hyperbaric Oxygenation. Neoplasm Recurrence, Local / surgery. Radiosurgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):236-41 [10390002.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):88-92 [10638972.001]
  • [Cites] Int J Cancer. 2001 Oct 20;96(5):320-5 [11582585.001]
  • [Cites] Radiother Oncol. 2003 Apr;67(1):63-7 [12758241.001]
  • [Cites] Br J Radiol. 1989 Aug;62(740):679-94 [2670032.001]
  • [Cites] J Neurooncol. 2002 May;58(1):47-52 [12160140.001]
  • [Cites] Stereotact Funct Neurosurg. 1995;64 Suppl 1:249-57 [8584835.001]
  • [Cites] Neurosurgery. 1997 Oct;41(4):776-83; discussion 783-5 [9316038.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):67-74 [12007943.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1405-9 [2542195.001]
  • [Cites] Neurosurgery. 2000 May;46(5):1123-8; discussion 1128-30 [10807244.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):393-8 [9069312.001]
  • [Cites] Cancer Lett. 2001 Mar 26;164(2):149-54 [11179829.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):293-8 [10030252.001]
  • [Cites] Radiother Oncol. 1999 Nov;53(2):127-31 [10665789.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):421-6 [10974456.001]
  • [Cites] Neurosurgery. 1995 Feb;36(2):275-82; discussion 282-4 [7731507.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1133-41 [10613305.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):427-31 [8005794.001]
  • [Cites] Radiother Oncol. 1995 Nov;37(2):108-16 [8747934.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):1045-53 [8985026.001]
  • (PMID = 17120158.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Saito T, Arifin MT, Hama S, Kajiwara Y, Sugiyama K, Yamasaki F, Hidaka T, Arita K, Kurisu K: Survivin subcellular localization in high-grade astrocytomas: simultaneous expression in both nucleus and cytoplasm is negative prognostic marker. J Neurooncol; 2007 Apr;82(2):193-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survivin subcellular localization in high-grade astrocytomas: simultaneous expression in both nucleus and cytoplasm is negative prognostic marker.
  • However, there have been no reports about the significance of subcellularly localized survivin in high-grade astrocytomas.
  • The aim of the present study was to examine the relationship between prognosis and subcellular localization of survivin in high-grade astrocytoma.
  • METHODS: We immunohistochemically examined the pattern of subcellular localization of survivin expression (nuclear, cytoplasmic, or both) in 51 patients with high-grade astrocytoma (19 anaplastic astrocytomas; 32 glioblastomas).
  • We statistically examined the relationship between survivin localization and prognosis, using multivariate analysis including other clinicopathological factors (age, sex, WHO grade, extent of resection, MIB-1 labeling index, and expression of p53 and epidermal growth factor receptor).
  • CONCLUSIONS: We found that simultaneous expression of survivin in both the nucleus and cytoplasm is an important prognostic factor for high-grade astrocytoma.
  • The present findings indicate that subcellular localization of survivin expression is a reliable prognostic factor for patients with this tumor.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Cell Nucleus / metabolism. Cytoplasm / metabolism. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Inhibitor of Apoptosis Proteins. Male. Middle Aged. Prognosis. Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism. Retrospective Studies. Subcellular Fractions. Survival Rate. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Strahlenther Onkol. 2004 Jul;180(7):401-7 [15241527.001]
  • [Cites] J Neurooncol. 2005 Apr;72(2):151-6 [15925995.001]
  • [Cites] Exp Cell Res. 2002 Apr 15;275(1):44-53 [11925104.001]
  • [Cites] Eur J Surg Oncol. 2003 May;29(4):379-82 [12711293.001]
  • [Cites] J Neurooncol. 2005 May;72(3):231-8 [15937645.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3531-4 [15867343.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1682-8 [15117990.001]
  • [Cites] Oncogene. 2005 Mar 17;24(12):1994-2007 [15688031.001]
  • [Cites] Oncogene. 2005 Apr 14;24(16):2723-34 [15735764.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):115-9 [12556969.001]
  • [Cites] Cancer Lett. 2001 Feb 10;163(1):109-16 [11163114.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1063-8 [11844831.001]
  • [Cites] Cell Death Differ. 2002 Dec;9(12):1334-42 [12478470.001]
  • [Cites] Am J Pathol. 2004 Feb;164(2):501-10 [14742256.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5071-4 [9823313.001]
  • [Cites] Acta Oncol. 2003;42(5-6):582-8 [14596516.001]
  • [Cites] Br J Cancer. 2005 Jan 31;92(2):212-6 [15611788.001]
  • [Cites] Br J Cancer. 2006 Jan 16;94(1):108-14 [16404364.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1077-83 [12569609.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Ann Oncol. 2006 Jun;17 Suppl 7:vii27-9 [16760287.001]
  • [Cites] Mod Pathol. 2004 Nov;17(11):1378-85 [15195112.001]
  • [Cites] Br J Cancer. 2003 Apr 7;88(7):1077-83 [12671708.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):127-34 [10656440.001]
  • [Cites] Mol Cancer. 2005 Mar 02;4(1):11 [15743529.001]
  • [Cites] Int J Cancer. 2005 Apr 20;114(4):509-12 [15578717.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1654-60 [15520067.001]
  • (PMID = 17151933.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Tumor Suppressor Protein p53; 0 / epidermal growth factor receptor-neu receptor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


78. Hanse MC, Franssen JH, Sleeboom HP, Hoffmann CF, Taal W: Two exceptional phenomena in an anaplastic oligo-astrocytoma. J Neurooncol; 2006 Jun;78(2):197
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two exceptional phenomena in an anaplastic oligo-astrocytoma.
  • [MeSH-major] Astrocytoma / secondary. Brain Neoplasms / pathology. Neoplasm Recurrence, Local / complications. Sagittal Sinus Thrombosis / etiology. Spinal Cord Neoplasms / secondary
  • [MeSH-minor] Adult. Cervical Vertebrae. Female. Functional Laterality. Humans

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16575535.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


79. Quaranta M, Divella R, Daniele A, Di Tardo S, Venneri MT, Lolli I, Troccoli G: Epidermal growth factor receptor serum levels and prognostic value in malignant gliomas. Tumori; 2007 May-Jun;93(3):275-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Increased EGFR expression might therefore be a strong prognostic feature in multiple tumor types, and inhibition of its cellular actions may have substantial therapeutic benefit.
  • METHODS AND STUDY DESIGN: Serum samples obtained from 50 healthy individuals and 65 brain cancer patients (35 glioblastoma multiforme and 30 anaplastic astrocytomas) were collected before and after treatment and assayed for EGFR extracellular domain serum concentrations by a sandwich ELISA.
  • There was a significant difference in the mean serum levels of EGFR between glioblastoma multiforme patients (96.2 +/- 12 ng/ml) and anaplastic astrocytoma patients (71.6 +/- 18 ng/ml, P = 0.04).
  • For all patients, median overall survival was 13 months (anaplastic astrocytoma, 18 months; glioblastoma multiforme, 12.5 months).
  • In 47 patients with high EGFR serum levels, overall survival was reduced (P = 0.01), with a median survival time corresponding to 11.5 months (anaplastic astrocytoma, 14.5 months; glioblastoma multiforme, 10.5 months).
  • [MeSH-major] Biomarkers, Tumor / blood. Brain Neoplasms / blood. Glioma / blood. Neoplasm Proteins / blood. Receptor, Epidermal Growth Factor / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / blood. Astrocytoma / drug therapy. Astrocytoma / mortality. Astrocytoma / radiotherapy. Astrocytoma / surgery. Chemotherapy, Adjuvant. Combined Modality Therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Disease-Free Survival. Enzyme-Linked Immunosorbent Assay. Female. Follow-Up Studies. Glioblastoma / blood. Glioblastoma / drug therapy. Glioblastoma / mortality. Glioblastoma / radiotherapy. Glioblastoma / surgery. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Protein Structure, Tertiary. Radiotherapy, Adjuvant. Signal Transduction. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17679463.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 7GR28W0FJI / Dacarbazine; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; YF1K15M17Y / temozolomide
  •  go-up   go-down


80. Marcus HJ, Carpenter KL, Price SJ, Hutchinson PJ: In vivo assessment of high-grade glioma biochemistry using microdialysis: a study of energy-related molecules, growth factors and cytokines. J Neurooncol; 2010 Mar;97(1):11-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo assessment of high-grade glioma biochemistry using microdialysis: a study of energy-related molecules, growth factors and cytokines.
  • This study's objective was to utilise microdialysis to monitor levels of glucose, lactate, pyruvate, glutamate and glycerol in patients following surgery for intrinsic brain tumours, and to assess the concentration of growth factors, cytokines and other proteins involved in the pathogenesis of high-grade gliomas in vivo.
  • Eight patients with suspected high-grade gliomas were studied.
  • Histology demonstrated WHO IV glioblastoma in five cases, WHO III anaplastic astrocytoma in two cases, and one cerebral lymphoma.
  • In the high-grade gliomas (WHO IV and III), tumour margin microdialysates consistently showed significantly lower glucose, higher lactate/pyruvate (L/P) ratio, higher glutamate and higher glycerol, relative to peritumour microdialysates (P < 0.05).
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Hormonal / pharmacology. Dexamethasone / pharmacology. Female. Glucose / metabolism. Glutamic Acid / metabolism. Glycerol / metabolism. Humans. Lactic Acid / metabolism. Male. Matrix Metalloproteinase 9 / metabolism. Microdialysis / methods. Middle Aged. Pyruvic Acid / metabolism. Tissue Inhibitor of Metalloproteinase-1 / metabolism. Tissue Inhibitor of Metalloproteinase-2 / metabolism

  • Genetic Alliance. consumer health - Glioma.
  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. LACTIC ACID .
  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. GLYCERIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann N Y Acad Sci. 1999;886:236-9 [10667228.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12 (19):5698-704 [17020973.001]
  • [Cites] Brain Tumor Pathol. 2004;21(3):105-12 [15696970.001]
  • [Cites] Int J Dev Neurosci. 1999 Aug-Oct;17(5-6):495-502 [10571411.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):122-33 [15831231.001]
  • [Cites] Nature. 1985 Jan 10-18;313(5998):144-7 [2981413.001]
  • [Cites] J Cell Sci. 1997 Oct;110 ( Pt 19):2473-82 [9410885.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] Eur J Clin Pharmacol. 1983;24(1):103-8 [6832191.001]
  • [Cites] Neoplasia. 1999 Aug;1(3):208-19 [10935475.001]
  • [Cites] Physiol Meas. 2005 Aug;26(4):423-8 [15886437.001]
  • [Cites] Curr Med Chem. 2007;14(14):1525-37 [17584061.001]
  • [Cites] J Neuroimmunol. 1997 Sep;78(1-2):152-61 [9307240.001]
  • [Cites] J Neurosurg. 2001 Mar;94(3):464-73 [11235952.001]
  • [Cites] Science. 2006 May 26;312(5777):1158-9 [16728625.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2894-901 [12231534.001]
  • [Cites] Int J Cancer. 1997 Jun 11;71(6):1066-76 [9185713.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):300-5 [9950501.001]
  • [Cites] J Physiol. 2007 May 1;580(Pt.3):937-49 [17317742.001]
  • [Cites] J Clin Neurosci. 2005 Nov;12(8):930-3 [16326273.001]
  • [Cites] Br J Neurosurg. 2007 Apr;21(2):204-9 [17453790.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):297-310 [16389942.001]
  • [Cites] J Neurooncol. 2005 Feb;71(3):287-93 [15735919.001]
  • [Cites] Biochim Biophys Acta. 2000 Mar 7;1477(1-2):267-83 [10708863.001]
  • [Cites] Cancer Res. 1996 Jul 15;56(14):3196-8 [8764105.001]
  • [Cites] J Neurooncol. 2006 Dec;80(3):285-93 [16773220.001]
  • [Cites] J Neurooncol. 2009 Jan;91(1):51-8 [18787762.001]
  • [Cites] Brain Tumor Pathol. 2003;20(2):39-45 [14756439.001]
  • [Cites] J Neurosurg. 1992 Jan;76(1):72-80 [1727172.001]
  • [Cites] Cancer Res. 1990 Oct 15;50(20):6683-8 [2208133.001]
  • [Cites] Bull Schweiz Akad Med Wiss. 1974 Jul;30(1-3):44-55 [4371656.001]
  • [Cites] J Neurosurg. 1987 Jun;66(6):865-74 [3033172.001]
  • [Cites] J Neurooncol. 2003 Jan;61(2):151-60 [12622454.001]
  • [Cites] Lancet. 1993 Jun 26;341(8861):1607-10 [8099987.001]
  • [Cites] Brain Pathol. 1990 Sep;1(1):12-8 [1669688.001]
  • [Cites] Acta Neurochir (Wien). 1993;121(3-4):199-205 [8512018.001]
  • [Cites] Eur J Anaesthesiol. 1996 May;13(3):269-78 [8737118.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1984 Oct;47(10):1087-90 [6502166.001]
  • [Cites] J Neurotrauma. 2007 Oct;24(10):1545-57 [17970618.001]
  • [Cites] Clin Exp Metastasis. 1999;17(7):555-66 [10845554.001]
  • [Cites] Int J Cancer. 2005 Jun 10;115(2):202-13 [15688401.001]
  • [Cites] Brain Tumor Pathol. 2001;18(1):13-21 [11517969.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Oct;84(19):6899-903 [3477813.001]
  • [Cites] Eur J Pharmacol. 2008 Sep 28;593(1-3):1-9 [18652821.001]
  • [Cites] J Neurooncol. 2000 Mar;47(1):11-22 [10930095.001]
  • [Cites] Radiology. 1990 Sep;176(3):791-9 [2389038.001]
  • [Cites] Neoplasia. 2007 Sep;9(9):777-87 [17898873.001]
  • [Cites] Acta Neurochir (Wien). 2009 Jan;151(1):51-61; discussion 61 [19099177.001]
  • [Cites] Dev Biol. 1974 Dec;41(2):255-66 [4548877.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2576-82 [12855633.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):657-64 [7674016.001]
  • [Cites] Trends Cell Biol. 2001 Nov;11(11):S37-43 [11684441.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):429-37 [9708803.001]
  • [Cites] J Neuroimmunol. 1994 Mar;50(2):187-94 [8120140.001]
  • [Cites] J Neurosurg. 2007 May;106(5):820-5 [17542525.001]
  • [Cites] Nature. 1974 Aug 2;250(465):422-4 [4368539.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):453-9 [9467557.001]
  • [Cites] Annu Rev Biochem. 1977;46:765-95 [197882.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1711-23 [16236742.001]
  • [Cites] Ann Neurol. 1992 Mar;31(3):319-27 [1637139.001]
  • [Cites] Acta Neurochir (Wien). 1992;114(1-2):8-11 [1561943.001]
  • [Cites] J Neurooncol. 2003 Sep;64(3):227-37 [14558598.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2000 Mar;278(3):E413-20 [10710495.001]
  • [Cites] J Neurosurg. 2000 Jul;93(1):37-43 [10883903.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Oct;27(9):1969-74 [17032877.001]
  • [Cites] J Neurosurg. 1996 Apr;84(4):606-16 [8613852.001]
  • [Cites] Biomed Pharmacother. 2005 Aug;59(7):359-64 [16084059.001]
  • [Cites] Brain Res Bull. 2000 Jan 1;51(1):29-34 [10654577.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] Cancer Res. 1991 Apr 15;51(8):2164-72 [2009534.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2008 Jul-Aug;79(1-2):59-65 [18762411.001]
  • [Cites] Biol Psychiatry. 1997 Mar 1;41(5):574-84 [9046990.001]
  • [Cites] Br J Cancer. 2001 Jul 6;85(1):55-63 [11437402.001]
  • [Cites] Neurosurgery. 2005 Jun;56(6):1264-8; discussion 1268-70 [15918942.001]
  • (PMID = 19714445.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0600986; United Kingdom / Medical Research Council / / G9439390; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Cytokines; 0 / Intercellular Signaling Peptides and Proteins; 0 / Tissue Inhibitor of Metalloproteinase-1; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; 33X04XA5AT / Lactic Acid; 3KX376GY7L / Glutamic Acid; 7S5I7G3JQL / Dexamethasone; 8558G7RUTR / Pyruvic Acid; EC 3.4.24.35 / Matrix Metalloproteinase 9; IY9XDZ35W2 / Glucose; PDC6A3C0OX / Glycerol
  •  go-up   go-down


81. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A: Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol; 2009 Oct;118(4):469-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
  • Somatic mutations in the IDH1 gene encoding cytosolic NADP+-dependent isocitrate dehydrogenase have been shown in the majority of astrocytomas, oligodendrogliomas and oligoastrocytomas of WHO grades II and III.
  • Preliminary data suggest an importance of IDH1 mutation for prognosis showing that patients with anaplastic astrocytomas, oligodendrogliomas and oligoastrocytomas harboring IDH1 mutations seem to fare much better than patients without this mutation in their tumors.
  • We found 165 IDH1 (72.7%) and 2 IDH2 mutations (0.9%) in 227 diffuse astrocytomas WHO grade II, 146 IDH1 (64.0%) and 2 IDH2 mutations (0.9%) in 228 anaplastic astrocytomas WHO grade III, 105 IDH1 (82.0%) and 6 IDH2 mutations (4.7%) in 128 oligodendrogliomas WHO grade II, 121 IDH1 (69.5%) and 9 IDH2 mutations (5.2%) in 174 anaplastic oligodendrogliomas WHO grade III, 62 IDH1 (81.6%) and 1 IDH2 mutations (1.3%) in 76 oligoastrocytomas WHO grade II and 117 IDH1 (66.1%) and 11 IDH2 mutations (6.2%) in 177 anaplastic oligoastrocytomas WHO grade III.
  • We report on an inverse association of IDH1 and IDH2 mutations in these gliomas and a non-random distribution of the mutation types within the tumor entities.
  • IDH1 mutations of the R132C type are strongly associated with astrocytoma, while IDH2 mutations predominantly occur in oligodendroglial tumors.
  • In addition, patients with anaplastic glioma harboring IDH1 mutations were on average 6 years younger than those without these alterations.
  • [MeSH-minor] Adult. Age Factors. Brain / pathology. Cell Differentiation. DNA Mutational Analysis. Female. Humans. Male. Middle Aged. Mutation. Prognosis. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19554337.001).
  • [ISSN] 1432-0533
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 1.1.1.41 / Isocitrate Dehydrogenase
  •  go-up   go-down


82. Radulović D: [Natural history of supratentorial low-grade astrocytoma: case report]. Srp Arh Celok Lek; 2006 Nov-Dec;134(11-12):537-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Natural history of supratentorial low-grade astrocytoma: case report].
  • Low-grade astrocytomas comprise a group of primary brain neoplasms with relatively low anaplastic potential, although through time they tend to behave more aggressively.
  • This report presents a natural history of a patient with low grade astrocytoma.
  • Initial computerized tomography and magnetic resonance of brain revealed oval, 4 cm in diameter, lesion in the left parietal region that was considered as low-grade glioma.
  • Repeated computerized tomography showed huge tumor in the left frontoparietal region at the site of previous lesion.
  • Urgent left frontoparietal craniotomy and reduction of tumor were performed.
  • The described patient with low-grade astrocytoma lived without any oncological treatment eight years and four months from the time when diagnosis was made until intracranial herniation.
  • The natural history of disease in presented patient indicated that rational therapeutic strategy, for low-grade astrocytoma with epilepsy only, would be deferral of surgery until the time of manifestation of neurological or radiological deterioration.
  • [MeSH-major] Astrocytoma. Brain Neoplasms. Parietal Lobe
  • [MeSH-minor] Adult. Humans. Male

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17304770.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


83. Ishii D, Natsume A, Wakabayashi T, Hatano H, Asano Y, Takeuchi H, Shimato S, Ito M, Fujii M, Yoshida J: Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas. Neurol Med Chir (Tokyo); 2007 Aug;47(8):341-9; discussion 350
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Promoter methylation of the deoxyribonucleic acid (DNA) repair gene, O(6)-methylguanine-DNA methyltransferase (MGMT), is associated with improved outcome of patients with glioblastoma multiforme and anaplastic astrocytoma treated with temozolomide (TMZ).
  • Molecular genetic analysis of loss of heterozygosity (LOH) of 1p, 19q, or 10q, p53 mutation, and MGMT promoter methylation was performed in 44 assessable tumor specimens obtained from 46 patients with recurrent malignant gliomas, including 21 with glioblastoma multiforme, 17 with anaplastic astrocytoma, and eight with anaplastic oligoastrocytoma, which have heterogeneous features and variable histological diagnosis, to assess the correlation with the response to TMZ.
  • [MeSH-major] Brain Neoplasms / genetics. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Dacarbazine / analogs & derivatives. Drug Resistance, Neoplasm / genetics. Glioma / genetics. Mutation / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents, Alkylating / pharmacology. Antineoplastic Agents, Alkylating / therapeutic use. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. DNA Methylation. DNA Mutational Analysis. DNA Repair / genetics. Female. Genetic Markers / genetics. Genetic Predisposition to Disease / genetics. Genetic Testing. Humans. Loss of Heterozygosity / genetics. Male. Middle Aged. Promoter Regions, Genetic / genetics. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721049.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Biomarkers, Tumor; 0 / Genetic Markers; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


84. Horbinski C, Wang G, Wiley CA: YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas. Int J Clin Exp Pathol; 2010 Jan 01;3(3):226-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas.
  • YKL-40 is a secreted chitinase-like molecule whose expression is associated with glioma grade.
  • A rank-order list of YKL-40 expression was determined immunohistochemically in 79 untreated high-grade adult glio-mas, including 28 anaplastic oligodendrogliomas (AOs) and 51 GBMs.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuro Oncol. 1999 Jan;1(1):44-51 [11550301.001]
  • [Cites] Oncogene. 2009 Dec 17;28(50):4456-68 [19767768.001]
  • [Cites] N Engl J Med. 2002 Feb 7;346(6):420-7 [11832530.001]
  • [Cites] Biochem J. 2002 Jul 1;365(Pt 1):119-26 [12071845.001]
  • [Cites] Cancer. 2002 Jul 15;95(2):267-74 [12124825.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4364-8 [12154041.001]
  • [Cites] Int J Cancer. 2002 Oct 10;101(5):454-60 [12216074.001]
  • [Cites] J Neurosurg. 2002 Dec;97(6):1397-401 [12507139.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4423-34 [14555515.001]
  • [Cites] Biochem J. 2004 Jun 15;380(Pt 3):651-9 [15015934.001]
  • [Cites] Cancer Res. 1997 Jan 15;57(2):304-9 [9000573.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1678-86 [15753362.001]
  • [Cites] Cancer Sci. 2005 Mar;96(3):183-90 [15771622.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2258-64 [15788675.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3326-34 [15867231.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8644-52 [16361549.001]
  • [Cites] Neurosurg Focus. 2005 Nov;19(5):E2 [16398466.001]
  • [Cites] Cancer. 2006 Mar 1;106(5):1130-9 [16456816.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3935-41 [16818690.001]
  • [Cites] J Biol Chem. 2006 Oct 6;281(40):29583-96 [16882657.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Dec;65(12):1149-56 [17146289.001]
  • [Cites] Gynecol Oncol. 2007 Feb;104(2):435-42 [17023034.001]
  • [Cites] World J Surg Oncol. 2007;5:17 [17286869.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1429-37 [17332285.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2288-94 [17538175.001]
  • [Cites] Clin Cancer Res. 2007 Jun 1;13(11):3244-9 [17545529.001]
  • [Cites] Int J Cancer. 2008 Feb 15;122(4):857-63 [17957792.001]
  • [Cites] Urol Oncol. 2008 Jan-Feb;26(1):47-52 [18190830.001]
  • [Cites] Eur J Haematol. 2008 Apr;80(4):310-7 [18182077.001]
  • [Cites] Int J Cancer. 2008 May 15;122(10):2187-98 [18092325.001]
  • [Cites] Am J Pathol. 2008 Jul;173(1):130-43 [18556781.001]
  • [Cites] Adv Ther. 2008 Aug;25(8):801-9 [18670741.001]
  • [Cites] FEBS Lett. 2008 Sep 22;582(21-22):3193-200 [18708058.001]
  • [Cites] Oncogene. 2008 Nov 6;27(52):6679-89 [18724390.001]
  • [Cites] Ann Oncol. 2009 Jan;20(1):71-7 [18723551.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):572-8 [19075264.001]
  • [Cites] BMC Cancer. 2009;9:8 [19134206.001]
  • [Cites] Brain Pathol. 2009 Jul;19(3):439-48 [18652591.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Oct 23;388(3):511-6 [19666003.001]
  • [Cites] Hum Pathol. 2009 Dec;40(12):1790-7 [19765801.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):196-201 [11801559.001]
  • (PMID = 20224722.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / K24 MH001717; United States / PHS HHS / / K24 M401717
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adipokines; 0 / CHI3L1 protein, human; 0 / Glycoproteins; 0 / Lectins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2836500
  • [Keywords] NOTNLM ; 10q / 1p19q / EGFR / YKL-40 / glioblastoma / oligodendroglioma
  •  go-up   go-down


85. Mohile NA, Forsyth P, Stewart D, Raizer JJ, Paleologos N, Kewalramani T, Louis DN, Cairncross JG, Abrey LE: A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis. J Neurooncol; 2008 Sep;89(2):187-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis.
  • BACKGROUND: Anaplastic oligodendrogliomas (AO) and anaplastic oligoastrocytomas (AOA) are currently treated with a combination of surgery, radiotherapy and chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / therapy. Brain Neoplasms / therapy. Oligodendroglioma / therapy. Radiotherapy, Adjuvant / methods
  • [MeSH-minor] Adult. Busulfan / administration & dosage. Combined Modality Therapy / methods. Female. Follow-Up Studies. Humans. Karnofsky Performance Status. Lomustine / administration & dosage. Male. Middle Aged. Procarbazine / administration & dosage. Retrospective Studies. Survival Analysis. Thiotepa / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuro Oncol. 2007 Jul;9(3):314-8 [17435180.001]
  • [Cites] J Clin Oncol. 1994 Mar;12(3):627-42 [8120563.001]
  • [Cites] J Neurooncol. 2003 Nov;65(2):127-34 [14686732.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):156-63 [17541945.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] Neurology. 1999 Sep 22;53(5):1141-3 [10496285.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):183-8 [16524945.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3599-604 [9808553.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • (PMID = 18458821.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; 905Z5W3GKH / Thiotepa; G1LN9045DK / Busulfan
  •  go-up   go-down


86. Chamberlain MC, Tsao-Wei DD, Groshen S: Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma. Cancer; 2006 Jan 1;106(1):172-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma.
  • BACKGROUND: A prospective Phase II study of cyclophosphamide (CYC) was conducted in adult patients with recurrent temozolomide-refractory anaplastic astrocytoma (AA) with a primary objective of evaluating 6-month progression-free survival (PFS).
  • Time to tumor progression ranged from 2-19 months (median, 4 mos; 95% CI, 2-6 mos).
  • CONCLUSIONS: CYC demonstrated modest efficacy with acceptable toxicity in this cohort of adult patients with recurrent anaplastic astrocytoma, all of whom had failed prior TMZ chemotherapy.
  • [MeSH-major] Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Cyclophosphamide / therapeutic use. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy
  • [MeSH-minor] Adult. Anaplasia. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Alkylating / therapeutic use. Drug Administration Schedule. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Prospective Studies

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16323194.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


87. Ellis JA, Waziri A, Balmaceda C, Canoll P, Bruce JN, Sisti MB: Rapid recurrence and malignant transformation of pilocytic astrocytoma in adult patients. J Neurooncol; 2009 Dec;95(3):377-382
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid recurrence and malignant transformation of pilocytic astrocytoma in adult patients.
  • Pilocytic astrocytoma is a slow-growing, circumscribed glioma that most frequently occurs within the pediatric population.
  • In general, surgical resection for pilocytic astrocytoma is thought to be curative with tumor recurrence or malignant transformation being relatively rare.
  • However, there have been very few studies specifically looking at the prognosis for adult patients diagnosed with pilocytic astrocytoma.
  • To evaluate the frequency of recurrence and malignant transformation of pilocytic astrocytoma in adults, we performed a retrospective analysis of all adult patients who underwent surgical resection for this tumor at our institution over a period of 10 years.
  • A high rate of malignant transformation was observed in the patients that underwent repeat surgery with 75% (3/4) progressing to anaplastic astrocytoma on pathological examination.
  • This study provides further evidence that the clinical course of a subset of adult patients with pilocytic astrocytoma will not be benign.
  • The potential for rapid tumor recurrence and malignant transformation necessitates careful post-operative follow-up for adult patients with this tumor.
  • [MeSH-major] Astrocytoma / mortality. Astrocytoma / pathology. Brain Neoplasms / mortality. Brain Neoplasms / pathology. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Cell Transformation, Neoplastic. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Retrospective Studies. World Health Organization. Young Adult

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 1997 Jan;13(1):17-23 [9083697.001]
  • [Cites] Br J Neurosurg. 2004 Dec;18(6):613-6 [15799194.001]
  • [Cites] J Neurosurg. 2003 Jun;98(6):1170-4 [12816259.001]
  • [Cites] Neurology. 2006 Jan 10;66(1):127-30 [16401863.001]
  • [Cites] Cancer. 2007 Dec 15;110(12 ):2799-808 [17973253.001]
  • [Cites] Oncogene. 2006 Feb 9;25(6):907-16 [16170340.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(3):341-6 [10819266.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):76-84 [15665281.001]
  • [Cites] J Neurosurg. 1985 Sep;63(3):382-6 [4020465.001]
  • [Cites] Acta Neurochir (Wien). 1986;81(3-4):90-3 [3751698.001]
  • [Cites] Childs Nerv Syst. 2005 Nov;21(11):940-4 [16044344.001]
  • [Cites] Childs Nerv Syst. 2001 Sep;17(9):503-11 [11585322.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2968-73 [12885817.001]
  • [Cites] Br J Ophthalmol. 2008 Jan;92(1):40-6 [17962395.001]
  • [Cites] Acta Neuropathol. 2009 Jun;117(6):657-65 [19271226.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1153-60 [15001258.001]
  • [Cites] Neurosurgery. 1991 Apr;28(4):606-9 [2034360.001]
  • [Cites] Surg Neurol. 1993 May;39(5):360-4 [8493594.001]
  • (PMID = 19533024.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Miyajima Y, Sato Y, Oka H, Utsuki S, Kondo K, Tanizaki Y, Nagashio R, Tsuchiya B, Okayasu I, Fujii K: Prognostic significance of nuclear DJ-1 expression in astrocytoma. Anticancer Res; 2010 Jan;30(1):265-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of nuclear DJ-1 expression in astrocytoma.
  • The present study was conducted to determine whether any correlation exists between the expression of DJ-1 and WHO grading of the tumor or patient prognosis, and to analyze the function of this oncogene in astrocytomas.
  • Twenty-nine formalin-fixed and paraffin-embedded glioblastomas (grade IV), 21 anaplastic astorocytomas (grade III), and 14 diffuse astrocytomas (grade II) were immunohistochemically studied to identify the expression of DJ-1 protein.
  • The expression of DJ-1 was detected both in the nucleus and cytoplasm of tumor cells; however, such expression varied from case to case.
  • The present study demonstrated that the survival of patients with astrocytomas was correlated with the nuclear DJ-1 status of the tumor.
  • We herein demonstrated for the first time that the DJ-1 molecule might therefore play an important role as a tumor suppressor in astrocytomas.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Oncogene Proteins / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Nucleus / metabolism. Female. Humans. Immunohistochemistry. Intracellular Signaling Peptides and Proteins. Male. Middle Aged. Predictive Value of Tests. Prognosis. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20150646.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Oncogene Proteins; 0 / PARK7 protein, human
  •  go-up   go-down


89. Malhan P, Husain N, Bhalla S, Gupta RK, Husain M: Proliferating cell nuclear antigen, p53 and micro vessel density: Grade II vs. Grade III astrocytoma. Indian J Pathol Microbiol; 2010 Jan-Mar;53(1):20-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proliferating cell nuclear antigen, p53 and micro vessel density: Grade II vs. Grade III astrocytoma.
  • Histological classification and grading are prime procedures in the management of patients with astrocytoma, providing vital data for therapeutic decision making and prognostication.
  • However, it has limitations in assessing biological